SlideShare a Scribd company logo
2014 REPORT 
PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES 
Biopharmaceutical Company Researchers Are 
Developing More Than 40 Medicines and Vaccines 
For HIV Infection Treatment and Prevention 
Globally, approximately 35 million people 
are infected with human immunodefi - 
ciency virus (HIV), the virus that causes 
acquired immune defi ciency syndrome 
(AIDS). However, new infections have 
dropped by 38 percent since 2001, 
according to UNAIDS, the Joint United 
Nations Programme on HIV/AIDS. 
In the United States, more than 
1.1 million people are living with HIV 
and 15.8 percent of those are unaware 
they are infected, according to the 
U.S. Centers for Disease Control and 
Prevention (CDC). Although the U.S. 
HIV/AIDS-related death rate has fallen 
by more than 80 percent since the 
introduction of antiretroviral therapies in 
1995, new HIV infections have stabilized 
at approximately 50,000 each year, 
according to the CDC. 
Since AIDS was fi rst reported in 1981, 
nearly 40 medicines have been approved 
to treat HIV infection in the United 
States. Although those medicines 
have made HIV infection a manageable 
chronic disease and helped to prolong the 
lives of infected patients, opportunities 
for even greater progress remain. 
Biopharmaceutical research companies 
are developing 44 medicines and 
vaccines for HIV infection, focusing on 
improved treatment regimens, more 
effective therapies, and preventative 
vaccines. These medicines and vaccines 
are either in clinical trials or awaiting 
review by the U.S. Food and Drug 
Administration (FDA). 
The 44 medicines and vaccines in the 
development pipeline include: 
• A fi rst-in-class medicine intended to 
prevent HIV from breaking through 
the cell membrane. 
• A cell therapy that modifi es a 
patient’s own cells in an attempt to 
make them resistant to HIV. 
MEDICINES IN DEVELOPMENT 
HIV/AIDS 
Medicines and Vaccines in 
Development for HIV Infection 
25 
Antivirals 
Cell/Gene Therapy 
Vaccines 
3 
16 
Application 
Submitted 
Phase III 
Phase II 
Phase I 
Some medicines are listed in more than 
one category. 
Contents 
HIV Medicines and Vaccines in 
Development ......................................2 
Incremental Innovation in 
HIV/AIDS Treatment .......................... 4 
Access to HIV/AIDS Medicines in 
Exchange Plans ...................................5 
Facts About HIV/AIDS ........................7 
Medicines and Vaccines in 
Development Chart ............................ 8 
Approved Medicines 
for HIV/AIDS ................................... 13 
The Drug Discovery, Development 
and Approval Process ........................ 15
Key Issues 
• A therapeutic vaccine designed to induce responses from 
T cells that play a role in immune protection against viral 
infections. 
The development of new, innovative therapies would not be 
possible without the patients who volunteer to participate in 
clinical trials. Currently, there are 94 active clinical trials for 
HIV infection medicines and vaccines in the United States. 
Of those, 43 have not yet started recruiting patients or have 
just begun to seek volunteers to participate; the other 51 are 
ongoing but not recruiting new patients.* 
Researching and developing new medicines remains a risky 
investment and a lengthy process. On average, it costs 
$1.2 billion and takes between 10–15 years to bring a new 
medicine to patients. Despite the risks, America’s 
biopharmaceutical research companies are continuing their 
efforts to develop novel and more effective treatments, 
vaccines to prevent HIV infection, and potentially a cure. 
HIV Medicines and Vaccines in 
Development 
Biopharmaceutical research companies are investigating 
new ways to treat and prevent HIV infection. Potential 
therapies being developed for HIV infection include: 
HIV/AIDS IN THE 
UNITED STATES 
44 MEDICINES & VACCINES 
IN DEVELOPMENT 
for HIV infection 
25 
Antivirals 
3 16 Cell/Gene Therapy 
Source: 2014 PhRMA Medicines in Development for HIV/AIDS, PhRMA. 
Vaccines 
Attachment Inhibitor—A new class of HIV medicines is 
intended to protect cells from HIV infection by preventing 
the virus from attaching to new cells and breaking through 
the cell membrane. One attachment inhibitor in development 
attaches to gp120, a part of the virus, and inhibits the entry 
of the virus into cells by blocking the interaction between 
gp120 and the cell receptors. 
Gene Modifi cation—CCR5 is a co-receptor on the surface 
of cells that allows HIV to enter and infect T cells. Without 
this receptor on the cell surface, it is more diffi cult for HIV 
to infect the cells. One cell therapy currently in clinical trials 
is designed to modify the DNA sequence encoding CCR5 
with the intent of making the patient’s own cells resistant to 
infection by HIV. The patient’s cells are extracted, modifi ed, 
and then reinserted into the patient. The goal of this therapy 
is to provide the patient with a population of cells that can 
fi ght HIV as well as the opportunistic infections from which 
patients with HIV often suffer. 
Inducing T Cell Responses—Another therapeutic vaccine in 
development is designed to induce CD4+ T cell responses in 
HIV-infected people. CD4+ T cells play a key role in immune 
protection against viral infections. Defi cits in CD4+ T cells are 
associated with virus reactivation, vulnerability to opportunistic 
infections, and poor vaccine effi cacy. 
HIV/AIDS IN THE 
UNITED STATES 
>1.1 MILLION 
living with HIV infection 
PLUS APPROXIMATELY 
NEW HIV INFECTIONS ANNUALLY 
Source: U.S. Centers for Disease Control and Prevention (CDC). 
50,000 
*Source: www.clinicaltrials.gov, search performed 8/5/2014. Search criteria: HIV infection, United States, Phase 0, 1, 2, 3; industry only. 
2 Medicines in Development HIV/AIDS 2014
Key Issues 
2014 RESEARCH & HOPE AWARDS 
The PhRMA Research & Hope Awards recognize advances made across a critical disease 
or health condition by individuals or organizations in the biopharmaceutical sector, 
academia, government, and provider and patient organizations. 
On September 10, 2014, PhRMA, along with distinguished members of the medical, patient 
and provider communities, presented the third annual Research & Hope Awards. This 
year’s program honored innovators in the area of HIV/AIDS, including recent advances in 
the prevention and treatment of the disease. Within the “Excellence in Research” categories, honorees 
represented the spectrum of the ecosystem—scientists working in academic research institutions, 
biopharmaceutical research companies, and patient organizations. Awardees included: 
THE RESEARCH & HOPE AWARD FOR ACADEMIC RESEARCH 
This award is presented to individuals or a team from an academic institution for 
outstanding research in the area of HIV/AIDS. 
2014 Award presented to: 
Raymond F. Schinazi, Ph.D., Hon. D.Sc., Emory University 
THE RESEARCH & HOPE AWARD FOR BIOPHARMACEUTICAL INDUSTRY RESEARCH 
This award is presented to individuals or a team from a biopharmaceutical company for 
outstanding research in the area of HIV/AIDS. 
2014 Award presented to: 
Bristol-Myers Squibb Virology Team 
Dennis Michael Grasela, Pharm.D., Ph.D.; George Hanna, M.D.; 
John F. Kadow, Ph.D.; Mark Krystal, Ph.D.; Nick A. Meanwell, Ph.D. 
THE RESEARCH & HOPE AWARD FOR PATIENT AND COMMUNITY HEALTH 
This award is presented to an individual or organization that has had a signifi cant impact 
educating patients and health care providers about the importance of treatment and 
prevention against HIV infection in their community. 
2014 “Visibility and Progress” Award presented to: 
Hydeia Broadbent 
2014 “Community Champion” Award presented to: 
Kathie Hiers, AIDS Alabama 
2014 “Excellence in Advocacy and Activism” Award presented to: 
Phill Wilson, Black AIDS Institute 
To learn more about the dedicated researchers honored with the 2014 Research & Hope Awards, please 
visit www.phrma.org/awards. 
Medicines in Development HIV/AIDS 2014 3
Key Issues 
Incremental Innovation in 
HIV/AIDS Treatment 
Over the last two decades, research advances have 
transformed treatment for many patients infected with HIV. 
In that time, HIV/AIDS has moved from an acute, fatal 
illness to a chronic disease, managed by effective treatment 
regimens. In the United States, death rates have fallen by more 
than 80 percent since 1995 as a result of the development 
“Developing a safe and su ciently 
e ective HIV vaccine is essential if 
we are to achieve a timely and 
durable end to the global HIV/AIDS 
pandemic.” 
— Anthony S. Fauci, M.D., NIAID Director 
and introduction of multiple drugs used in innovative 
combinations, known as antiretroviral therapy (ART). 
For HIV/AIDS, the introduction of novel therapies and 
continuous research into their best use in patients has revealed 
value beyond what was known at the time of approval 
HIV/AIDS IN THE 
UNITED STATES 
THEN AND NOW 
Since HIV/AIDS was first recognized in 1981, advances in medicines have helped 
lower the death rate by 83%. Prior to 1995, when the first antiretroviral treatment 
was approved by the FDA, an HIV diagnosis was a death sentence. Now, thanks to 
medicines developed by biopharmaceutical scientists and their research partners, 
it is a chronic condition with manageable costs and patients are able to reach 
nearly a full life expectancy. 
ARTHUR ASHE 
Due to the lack of effective 
medicines, Arthur Ashe 
succumbed to AIDS-related 
pneumonia at 50 years old 
in 1993, just 10 years after 
he contracted the disease 
and 5 years after diagnosis 
Source: Magic Johnson Foundation, Arthur Ashe Learning Center (AALC). 
MAGIC JOHNSON 
Despite being diagnosed 
with HIV/AIDS in 1991, 
Magic is expected to meet 
his full life expectancy due 
to the treatments available 
at the outset of his 
diagnosis 
by the FDA. This value has been realized over time as new 
treatments build on one another and real world knowledge is 
accumulated. Additional post-approval value for HIV/AIDS 
therapies include use in combination with other therapeutics, 
treatment earlier in the disease state, and use to prevent HIV 
transmission in certain situations. 
PDUFA V SEEKS TO GAIN PATIENT PERSPECTIVE 
As part of the reauthorization of the Prescription Drug User Fee Act in 2012 (PDUFA V), FDA committed 
to hold 20 Patient-Focused Drug Development (PFDD) meetings on a set of disease areas in order 
to gain the patient perspective on disease severity and unmet medical need. In June 2013, FDA 
conducted a PFDD public meeting on “HIV Patient-Focused Drug Development and HIV Cure 
Research” to get patient input on the impact of HIV on daily life, therapies currently available to 
treat the infection, and patients’ views on issues related to HIV research. Consideration of patients’ 
perception of the acceptable balance of known and possible risks and benefi ts has the potential to add 
crucial perspective when regulators are faced with diffi cult benefi t-risk decisions. 
4 Medicines in Development HIV/AIDS 2014
Key Issues 
HIV/AIDS IN THE 
UNITED STATES 
PROGRESS IN THE FIGHT 
1995: the first protease inhibitors were 
approved by the FDA, and the HIV/AIDS death 
rate decreased 67% over a few years 
2006: transmission rates 
between mother and infant 
dropped below 2% 
Source: Magic Johnson Foundation, Arthur Ashe Learning Center (AALC). 
2012: U.S. death 
rate dropped 83% 
Access to HIV/AIDS Medicines in 
Exchange Plans 
Prescription medicines are a crucial component of 
treatment for HIV/AIDS. Multidrug regimens have 
substantially reduced HIV progression to AIDS, 
opportunistic infections, hospitalizations, and death. 
Early ART regimens often required patients to take 
several pills multiple times a day. New formulations, 
such as single-tablets, reduce the patient’s pill burden 
dramatically, improving adherence and slowing disease 
progression. 
An analysis by Avalere Health, that was commissioned by 
PhRMA, offers insight into access to these medicines in 
the new health insurance exchanges. On average, health 
insurance exchange plans created by the Affordable Care 
Act offer HIV/AIDS medicines, but are less likely to cover 
combination medicines over other brand HIV/AIDS 
medicines. Exchange plans also impose high cost-sharing 
and utilization management to needed HIV/AIDS medicines. 
Highlights from the analysis include: 
• Formulary Coverage: Certain types of medicines are 
often excluded from the formulary. Compared to brand 
medicines that treat other conditions, HIV/AIDS 
medications are more likely to be on the formulary; 
however, combination therapies—which increasingly 
represent the standard-of-care in treatment of 
HIV/AIDS—are less likely than single-ingredient 
HIV/AIDS medications to be covered. Exchange plans 
cover single-source brand HIV/AIDS medicines 
(defi ned as medicines for which a generic equivalent is 
not available) 81 percent of the time, but only cover 
combination medicines 67 percent of the time. 
• Cost-Sharing: Medicines to treat HIV/AIDS are 
sometimes subject to high coinsurance. HIV/AIDS 
medicines are subject to coinsurance in approximately 
55 percent of plans, with an average coinsurance of 
35 percent for all medications and 37 percent for 
combination medicines. For a single HIV/AIDS medicine 
subject to a coinsurance of 35 percent, out-of-pocket 
costs could range from $1,100 to over $6,000 annually. 
HIV/AIDS IN THE 
UNITED STATES 
Frequency of COPAYMENT vs. COINSURANCE by 
Amount for HIV/AIDS Medicines in SILVER PLANS 
19% 
13% 
10% 
12% 
46% 
COPAYMENT 
HIV/AIDS CLASSES 
19% 
13% 
11% 
8% 
47% 
COPAYMENT 
COINSURANCE 
COMBINATION PRODUCTS 
40% 
31-40% 
21-30% 
0-20% 
Source: Access to HIV/AIDS Medications in Exchange Plans, PhRMA. 
Medicines in Development HIV/AIDS 2014 5
Key Issues 
HIV/AIDS IN THE 
UNITED STATES 
Utilization Management of 
HIV/AIDS MEDICINES 
26% 
74% 
8% 5% 
EXCHANGE PLANS 92% 95% 
UTILIZATION 
MANAGEMENT 
NO UTILIZATION 
MANAGEMENT 
EMPLOYER PLANS BENCHMARK PLANS 
Source: Access to HIV/AIDS Medications in Exchange Plans, PhRMA. 
• Access Limits: Medicines are more likely to be subject 
to utilization management—step therapy or prior 
authorization—in exchange plans than in employer or 
benchmark plans. For HIV/AIDS, utilization management 
is three times as likely in exchange plans compared to 
employer plans (26 percent compared to 8 percent of 
the time). 
PRE-EXPOSURE PROPHYLAXIS FOR AT-RISK POPULATIONS 
Health offi cials in the United States have recommended pre-exposure prophylaxis (PrEP) for Americans 
who are at risk of sexually acquired HIV infection. According to the CDC, such a prevention strategy 
could help decrease the estimated 50,000 new infections each year in the United States. This strategy 
has also been endorsed by the World Health Organization (WHO). 
Offi cials recommended that at-risk adult populations take Truvada® (emtricitabine and tenofovir 
disoproxil fumarate), the only antiretroviral medication currently approved for PrEP in the United 
States. Truvada is indicated for use in combination with safe sex practices for PrEP to reduce the risk 
of sexually acquired HIV infection in adults at high risk. 
The new guidelines are suggested for sexually active gay men who do not use condoms, heterosexual 
men and women with high-risk partners who do not use condoms, adults who have regular sex with 
anyone they know is already infected with HIV, and anyone who shares needles or injects drugs. 
Since 2010, three separate trials of Truvada in gay men, heterosexual couples, and intravenous drug 
users have shown that when taken daily, it can greatly reduce the chances of HIV infection. In the 
study of gay men, among the men who had taken the medicine every day, 99 percent were protected. 
6 Medicines in Development HIV/AIDS 2014
Facts 
Facts About HIV/AIDS 
HIV/AIDS Worldwide1 
• At the end of 2013, approximately 35 million people 
were living with HIV, and some 2.1 million people 
became newly infected globally. 
• Sub-Saharan Africa is the most affected region, with 
nearly 25 million people living with HIV in 2013. That 
region also accounts for almost 70 percent of the global 
total of new HIV infections. 
• In 2013, 12.9 million people living with HIV were receiving 
antiretroviral therapy (ART) globally. Of those, 11.7 million 
were receiving ART in low- and middle-income countries. 
Approximately 740,000 of them were children. 
• Pediatric coverage lags behind adults with fewer than 
1 in 4 children on ART, compared to 1 in 3 adults. 
Of all adults living with HIV, 38 percent were receiving 
treatment; however, just 24 percent of all children 
living with HIV were receiving those lifesaving medicines 
in 2013. 
• In 2013, 67 percent of the estimated 1.4 million pregnant 
women living with HIV in low- and middle-income countries 
received antiretroviral drugs to avoid transmission to their 
children, up from 47 percent in 2010. 
• HIV continues to be a major global public health issue, 
having claimed more than 39 million lives so far. In 2013, 
approximately 1.5 million people died from HIV-related 
causes. 
HIV/AIDS in the United States2 
• An estimated 1,144,500 people ages 13 and older 
are living with HIV infection, including 180,900 
(15.8 percent) who are unaware of their infection. Over 
the past decade, the number of people living with HIV 
has increased, while the annual number of new HIV 
infections has remained relatively stable. 
• The estimated incidence (new infections) of HIV has 
remained stable overall in recent years, at approximately 
50,000 new HIV infections per year. Within the overall 
estimates, however, some groups are affected more 
than others. Men who have sex with men continue to 
bear the greatest burden of HIV infection, and among 
races/ethnicities, African Americans continue to be 
disproportionately affected. 
• African Americans make up 12 percent of the U.S. 
population, but accounted for 44 percent of new HIV 
infections in 2010; Hispanics make up 16 percent of the 
population, but accounted for 21 percent of new HIV 
infections in 2010; and men who have sex with men 
account for 4 percent of the male population, but 
accounted for 78 percent of new infections in 2010 
among men and 63 percent of all new infections. 
• In 2011, an estimated 32,052 people were diagnosed 
with AIDS. Overall, an estimated 1,155,792 people in the 
United States have been diagnosed with AIDS. 
• An estimated 15,529 people with an AIDS diagnosis 
died in 2010, and approximately 636,000 people in the 
United States with an AIDS diagnosis have died overall. 
The deaths of people with an AIDS diagnosis can be 
due to any cause—that is, the death may or may not be 
related to AIDS. 
HIV/AIDS Economic Impact in the United States2 
• A large portion of the economic burden of HIV/AIDS is 
the medical cost of treating people with HIV. The average 
annual cost of HIV care in the ART era was estimated to 
be $23,000 per person in 2010 dollars. The most recent 
published estimate of lifetime HIV treatment costs was 
$379,668 in 2010 dollars. 
• The medical savings from HIV infections averted by U.S. 
prevention programs from 1991-2006 were estimated to 
be $129.9 billion with nearly 362,000 infections averted. 
• Nearly 30 years into the HIV epidemic, HIV continues 
to take a heavy toll in the United States. More than 
1.1 million people are currently living with HIV, nearly 
18,000 people with AIDS still die each year, and lifetime 
medical care for those who become infected with HIV 
each year is estimated to cost $20 billion. 
Sources: 
1. World Health Organization, www.who.int 
2. U.S. Centers for Disease Control and Prevention, 
www.cdc.gov 
Medicines in Development HIV/AIDS 2014 7
Medicines and Vaccines in Development for HIV/AIDS 
Antivirals 
Product Name Sponsor Indication Development Phase* 
‘572-Trii 
(abacavir/dolutegravir/ 
lamivudine  xed-dose 
combination) 
ViiV Healthcare 
Research Triangle Park, NC 
HIV-1 infection treatment application submitted 
amdoxovir RFS Pharma 
Tucker, GA 
HIV-1 infection treatment Phase II 
anti-PD-L1 
(BMS-936559) 
Bristol-Myers Squibb 
Princeton, NJ 
HIV-1 infection treatment Phase I 
apricitabine 
(ATC) 
Avexa 
Melbourne, Australia 
LINK Healthcare 
Singapore 
HIV-1 infection treatment 
(Fast Track) 
BMS-955176 Bristol-Myers Squibb 
Princeton, NJ 
HIV-1 infection treatment Phase II 
cenicriviroc 
(CCR2/CCR5 receptor 
antagonist) 
Tobira Therapeutics 
South San Francisco, CA 
HIV-1 infection treatment Phase II completed 
cobicistat 
(PK enhancer) 
Gilead Sciences 
Foster City, CA 
HIV infection treatment application submitted 
cobicistat/darunavir/ 
emtricitabine/ 
tenofovir alafenamide 
 xed-dose combination 
Gilead Sciences 
Foster City, CA 
HIV-1 infection treatment Phase II 
cobicistat/elvitegravir/ 
emtricitabine/ 
tenofovir alafenamide 
 xed-dose combination 
Gilead Sciences 
Foster City, CA 
HIV-1 infection treatment Phase III 
dapivirine 
(vaginal ring) 
International Partnership for 
Microbicides 
Silver Spring, MD 
Janssen RD Ireland 
Cork, Ireland 
HIV infection prevention Phase I 
*For more information about a specifi c medicine or company in this report, please use the website provided. 
www.viivhealthcare.com 
www.rfspharma.com 
www.bms.com 
Phase III 
www.avexa.com.au 
www.linkhealthcare.co 
www.bms.com 
www.tobiratherapeutics.com 
www.gilead.com 
www.gilead.com 
www.gilead.com 
www.ipmglobal.org 
8 Medicines in Development HIV/AIDS 2014
Medicines and Vaccines in Development for HIV/AIDS 
Antivirals 
Product Name Sponsor Indication Development Phase 
efavirenz/lamivudine/ 
tenofovir fumarate 
 xed-dose combination 
Mylan Laboratories 
Canonsburg, PA 
HIV-1 infection treatment application submitted 
www.mylan.com 
elvitegravir 
(integrase inhibitor) 
Gilead Sciences 
Foster City, CA 
HIV-1 infection treatment application submitted 
www.gilead.com 
F/TAF 
(emtricitabine/tenofovir 
alafenamide  xed-dose 
combination) 
Gilead Sciences 
Foster City, CA 
HIV-1 infection treatment Phase III 
www.gilead.com 
GSK2838232 
(antiviral maturation inhibitor) 
ViiV Healthcare 
Research Triangle Park, NC 
HIV-1 infection treatment Phase I 
www.viivhealthcare.com 
HIV attachment inhibitor 
(BMS-663068) 
Bristol-Myers Squibb 
Princeton, NJ 
HIV-1 infection treatment 
(Fast Track) 
Phase II 
www.bms.com 
ibalizumab 
(TMB-355) 
(viral entry inhibitor) 
US TaiMed Biologics 
Irvine, CA 
HIV-1 infection treatment 
(Fast Track) 
Phase II 
www.taimedbiologics.com 
lamivudine/raltegravir 
 xed-dose combination 
Merck 
Whitehouse Station, NJ 
HIV-1 infection treatment application submitted 
www.merck.com 
MK-1439 
(doravirine) 
Merck 
Whitehouse Station, NJ 
HIV-1 infection treatment Phase II 
www.merck.com 
Norvir® 
ritonavir 
powdered formulation 
AbbVie 
North Chicago, IL 
HIV infection treatment in clinical trials 
www.abbvie.com 
Prezista® darunavir 
and cobicistat (GS-9350) 
 xed-dose combination 
Janssen Research  Development 
Raritan, NJ 
HIV-1 infection treatment application submitted 
www.janssenrnd.com 
PRO 140 
(viral entry inhibitor) 
CytoDyn 
Vancouver, WA 
HIV-1 infection treatment Phase II completed 
www.cytodyn.com 
reformulated raltegravir 
(once daily) 
Merck 
Whitehouse Station, NJ 
HIV-1 infection treatment Phase III 
www.merck.com 
rilpivirine 
(long-acting intramuscular) 
Janssen Research  Development 
Raritan, NJ 
HIV-1 infection treatment Phase I 
www.janssenrnd.com 
S/GSK1265744 
(integrase inhibitor, long acting 
parenteral formulation) 
ViiV Healthcare 
Research Triangle Park, NC 
HIV-1 infection treatment Phase II 
www.viivhealthcare.com 
Medicines in Development HIV/AIDS 2014 9
Medicines and Vaccines in Development for HIV/AIDS 
Antivirals 
Product Name Sponsor Indication Development Phase 
tenofovir vaginal gel 
(NtRTI) 
CONRAD 
Arlington, VA 
HIV infection prevention Phase I 
www.conrad.org 
Cell Therapy/Gene Therapy 
Product Name Sponsor Indication Development Phase 
Cal-1 
(blood stem cell therapy) 
Calimmune 
Los Angeles, CA 
HIV-1 infection treatment Phase I/II 
www.calimmune.com 
MazF gene therapy Takara Bio 
Tokyo, Japan 
HIV-1 infection treatment Phase I 
www.takara-bio.com 
SB-728-T 
(CCR5 receptor modulator) 
Sangamo BioSciences 
Richmond, CA 
HIV infection treatment Phase II 
www.sangamo.com 
Vaccines 
Product Name Sponsor Indication Development Phase 
AGS-004 
(personalized immunotherapy) 
Argos Therapeutics 
Durham, NC 
HIV-1 infection treatment Phase II 
www.argostherapeutics.com 
GOVX-B11 
(clade B) 
(DNA/MVA vaccine) 
GeoVax Labs 
Atlanta, GA 
HIV infection prevention 
----------------------------------------- 
HIV infection treatment 
Phase II 
www.geovax.com 
----------------------------------------- 
Phase I 
www.geovax.com 
HIV recombinant vaccine GlaxoSmithKline 
Research Triangle Park, NC 
HIV-1 immunotherapy Phase II 
www.gsk.com 
HIV recombinant vaccine GlaxoSmithKline 
Research Triangle Park, NC 
HIV-1 infection prevention Phase I 
www.gsk.com 
10 Medicines in Development HIV/AIDS 2014
Medicines and Vaccines in Development for HIV/AIDS 
Vaccines 
Product Name Sponsor Indication Development Phase 
HIV vaccine Novartis Vaccines  Diagnostics 
Cambridge, MA 
National Institute of Allergy and 
Infectious Diseases 
Bethesda, MD 
HIV infection Phase I 
www.novartisvaccines.com 
HIV vaccine 
(Ad4-EnvC 150) 
PaxVax 
San Diego, CA 
National Institute of Allergy and 
Infectious Diseases 
Bethesda, MD 
HIV infection prevention Phase I 
www.paxvax.com 
HIV vaccine 
(Ad4-mGag) 
PaxVax 
Baltimore, MD 
National Institute of Allergy and 
Infectious Diseases 
Bethesda, MD 
HIV infection prevention Phase I 
www.paxvax.com 
HIV vaccine 
(SAV001) 
Sumagen Canada 
London, Canada 
HIV-1 infection prevention Phase I completed 
www.sumagen.co.kr 
HIVAX™ 
replication-defective HIV-1 vaccine 
GeneCure Biotechnologies 
Norcross, GA 
HIV-1 infection treatment Phase I 
www.genecure.com 
LFn-p24-B-C 
(HIV therapeutic vaccine) 
Haikou VTI Biological Institute 
Haikou City, China 
HIV-1 infection treatment with ART in clinical trials 
www.haikouvti.com/en 
PBSVax™ 
HIV-MAG DNA vaccine 
Profectus BioSciences 
Baltimore, MD 
HIV infection treatment 
----------------------------------------- 
HIV infection prevention 
Phase I 
www.profectusbiosciences.net 
----------------------------------------- 
Phase I 
www.profectusbiosciences.net 
Pennvax®-B 
DNA vaccine (clade B) 
Inovio Pharmaceuticals 
Blue Bell, PA 
HIV Vaccine Trials Network 
Seattle, WA 
HIV infection prevention and 
treatment 
Phase I completed 
www.inovio.com 
Pennvax®-G 
DNA vaccine (clades A, C, D) 
Inovio Pharmaceuticals 
Blue Bell, PA 
National Institute of Allergy and 
Infectious Diseases 
Bethesda, MD 
HIV infection prevention and 
treatment 
Phase I 
www.inovio.com 
Remune® 
HIV vaccine 
Immune Response BioPharma 
Atlantic City, NJ 
HIV-1 infection treatment Phase III 
www.immuneresponsebiopharma. 
com 
Medicines in Development HIV/AIDS 2014 11
Medicines and Vaccines in Development for HIV/AIDS 
Vaccines 
Product Name Sponsor Indication Development Phase 
RemuneX® 
HIV combination vaccine 
Immune Response BioPharma 
Atlantic City, NJ 
HIV-1 infection treatment Phase III 
www.immuneresponsebiopharma. 
com 
vacc-4x 
(intradermal vaccine) 
Bionor Pharma 
Oslo, Norway 
HIV-1 infection treatment combined 
with Revlimid® 
----------------------------------------- 
HIV-1 infection treatment combined 
with Istodax® 
Phase II 
www.bionorpharma.com 
----------------------------------------- 
Phase II 
www.bionorpharma.com 
Defi nitions 
Application Submitted—An application for marketing has been submitted by the company to the U.S. Food and Drug Administration (FDA). 
Fast Track—This designation is assigned by the FDA to facilitate the development and expedite the review of drugs to treat serious diseases and  ll unmet medical needs. 
When considering a drug company’s request for Fast Track designation for an investigational drug, the FDA evaluates whether the drug will a ect factors such as survival, 
day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one. Early and frequent communication 
between the FDA and a drug company is encouraged throughout the entire drug development and review process, once a drug receives Fast Track designation. The increase 
in communication can help to quickly resolve any questions or issues that arise, potentially leading to an earlier drug approval and access by patients. 
Phase I—Researchers test the investigational drug in a small group of people, usually between 20 and 100 healthy adult volunteers, to evaluate its initial safety and 
tolerability profile, determine a safe dosage range, and identify potential side effects. 
Phase II—The investigational drug is given to volunteer patients, usually between 100 and 500, to determine whether the drug is e ective, identify an optimal dose, and 
to further evaluate its short-term safety. 
Phase III—The investigational drug is given to a larger, more diverse patient population, often involving between 1,000 and 5,000 patients (but sometimes many more), 
to generate statistically signi cant evidence to con rm its safety and e ectiveness. Phase III studies are the longest studies and usually take place in multiple sites around 
the world. 
The content of this report has been obtained through public, government and industry sources, and the Adis “RD Insight” 
database based on the latest information. Report current as of August 5, 2014. The medicines in this report include 
medicines being developed by U.S.-based companies conducting trials in the United States and abroad, PhRMA-member 
companies conducting trials in the United States and abroad, and foreign companies conducting clinical trials in the United 
States. The information in this report may not be comprehensive. For more specifi c information about a particular product, 
contact the individual company directly or go to www.clinicaltrials.gov. The entire series of Medicines in Development is 
available on PhRMA’s website. 
A publication of PhRMA’s Communications  Public Affairs Department (202) 835-3460 
www.phrma.org | www.innovation.org | www.pparx.org 
Provided as a public service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association. 
Copyright © 2014 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if proper 
credit is given. 
Pharmaceutical Research and Manufacturers of America • 950 F Street, NW, Suite 300, Washington, DC 20004 
12 Medicines in Development HIV/AIDS 2014
Approved Medicines for HIV/AIDS 
Entry Inhibitors 
Selzentry® (maraviroc) ViiV Healthcare 
Fuzeon® (enfuvirtide) Genentech, Trimeris 
Integrase Inhibitor 
Isentress® (raltegravir) Merck 
Tivicay® (dolutegravir) ViiV Healthcare 
Nucleoside Reverse Transcriptase Inhibitors (NRTI) 
Combivir® (lamivudine/zidovudine) ViiV Healthcare 
Emtriva® (emtricitabine) Gilead Sciences 
Epivir® (lamivudine) ViiV Healthcare 
Epzicom® (abacavir/lamivudine) ViiV Healthcare 
Hivid® (zalcitabine) Roche, marketing discontinued 
Retrovir® (zidovudine) ViiV Healthcare 
Trizivir® (abacavir/lamivudine/zidovudine) ViiV Healthcare 
Videx® (didanosine) Bristol-Myers Squibb 
Videx® EC (didanosine delayed release) Bristol-Myers Squibb 
Zerit® (stavudine) Bristol-Myers Squibb 
Zerit XR® (stavudine extended release) Bristol-Myers Squibb, marketing discontinued 
Ziagen® (abacavir) ViiV Healthcare 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) 
Edurant® (rilpivirine) Janssen Therapeutics 
Intelence® (etravirine) Janssen Therapeutics 
Rescriptor® (delvaridine mesylate) ViiV Healthcare 
Sustiva® (efavirenz) Bristol-Myers Squibb 
Viramune® (nevirapine) Boehringer Ingelheim Pharmaceuticals 
Viramune XR® (nevirapine extended release) Boehringer Ingelheim Pharmaceuticals 
Medicines in Development HIV/AIDS 2014 13
Approved Medicines for HIV/AIDS 
Nucleotide Reverse Transcriptase Inhibitor (NtRTI) 
Viread® (tenofovir disoproxil fumarate) Gilead Sciences 
Protease Inhibitors 
Agenerase® (amprenavir) GlaxoSmithKline, Vertex Pharmaceuticals, marketing discontinued 
Aptivus® (tipranavir) Boehringer Ingelheim Pharmaceuticals 
Crixivan® (indinavir) Merck 
Fortovase® (saquinavir soft-gel) Roche, marketing discontinued 
Invirase® (saquinavir) Genentech 
Kaletra® (lopinavir/ritonavir) AbbVie 
Lexiva® (fosamprenavir) ViiV Healthcare, Vertex Pharmaceuticals 
Norvir® (ritonavir) AbbVie 
Prezista® (darunavir) Janssen Therapeutics 
Reyataz® (atazanavir) Bristol-Myers Squibb 
Viracept® (nelfi navir) ViiV Healthcare 
Combination Medicines 
NNRTI/NRTI/NtRTI 
Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) Bristol-Myers Squibb, Gilead Sciences 
NRTI/NNRTI/NtRTI 
Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) Gilead Sciences 
Integrase Inhibitor/PK Enhancer/NRTI/NtRTI 
Stribild® (elvitegravor/cobicistat/emtricitabine/tenofvoir disoproxil fumarate) Gilead Sciences 
NRTI/NtRTI 
Truvada® (emtricitabine/tenofovir disoproxil fumarate) Gilead Sciences 
14 Medicines in Development HIV/AIDS 2014
The Drug Discovery, Development and Approval Process 
Developing a new medicine takes an average of 10-15 years. 
Of the tens of thousands of compounds screened, only one is approved. 
The Drug Development and Approval Process 
The U.S. system of new drug approvals is 
perhaps the most rigorous in the world. 
It takes 10-15 years, on average, for an 
investigational drug to travel from the lab to U.S. 
patients, according to the Tufts Center for the 
Study of Drug Development. Tens of thousands 
of compounds may be screened early in 
development, but only one ultimately receives 
approval. Even medicines that reach clinical trials 
have only a 16 percent chance of being approved. 
On average, it costs a company $1.2 billion, 
including the cost of failures, to get one new 
medicine from the laboratory to U.S. patients, 
according to a 2007 study by the Tufts Center 
for the Study of Drug Development. More recent 
studies estimate the cost to be even higher. 
Once a new compound has been identifi ed in 
the laboratory, medicines are usually developed 
as follows: 
Preclinical Testing—A pharmaceutical company 
conducts laboratory and animal studies to show 
biological activity of the compound against the 
targeted disease, and the compound is evaluated 
for safety. 
Investigational New Drug Application (IND)— 
After completing preclinical testing, a company 
fi les an IND with the U.S. Food and Drug 
Administration (FDA) to begin to test the drug 
in people. The IND shows results of previous 
experiments; how, where and by whom the new 
studies will be conducted; the chemical structure 
of the compound; how it is thought to work in 
the body; any toxic effects found in the animal 
studies; and how the compound is manufactured. 
All clinical trials must be reviewed and approved 
by the Institutional Review Board (IRB) where 
the trials will be conducted. Progress reports on 
clinical trials must be submitted at least annually 
to FDA and the IRB. 
Clinical Trials, Phase I—Researchers test the 
drug in a small group of people, usually between 
20 and 100 healthy adult volunteers, to evaluate 
its initial safety and tolerability profi le, determine 
a safe dosage range, and identify potential side 
effects. 
Clinical Trials, Phase II—The drug is given 
to volunteer patients, usually between 100 and 
500, to see if it is effective, identify an optimal 
dose, and to further evaluate its short-term 
safety. 
Clinical Trials, Phase III—The drug is given to a 
larger, more diverse patient population, often 
involving between 1,000 and 5,000 patients 
(but sometimes many more), to generate 
statistically signifi cant evidence to confi rm its 
safety and effectiveness. They are the longest 
studies, and usually take place in multiple sites 
around the world. 
New Drug Application (NDA)/Biologic License 
Application (BLA)—Following the completion 
of all three phases of clinical trials, a company 
analyzes all of the data and fi les an NDA or BLA 
with FDA if the data successfully demonstrate 
both safety and effectiveness. The applications 
contain all of the scientifi c information that the 
company has gathered. Applications typically 
run 100,000 pages or more. 
Approval—Once FDA approves an NDA or 
BLA, the new medicine becomes available 
for physicians to prescribe. A company must 
continue to submit periodic reports to FDA, 
including any cases of adverse reactions and 
appropriate quality-control records. For some 
medicines, FDA requires additional trials 
(Phase IV) to evaluate long-term effects. 
Discovering and developing safe and effective 
new medicines is a long, diffi cult, and expensive 
process. PhRMA member companies invested 
an estimated $51.1 billion in research and 
development in 2013. 
Medicines in Development HIV/AIDS 2014 15
ful l 
color 
black 
white Pharmaceutical Research and Manufacturers of America 
950 F Street, NW, Washington, DC 20004 
www.phrma.org

More Related Content

What's hot

Adherencia al tarv en am latina y caribe
Adherencia al tarv en am latina y caribeAdherencia al tarv en am latina y caribe
Adherencia al tarv en am latina y caribe
Rosa Alcayaga
 
Understanding the needs of people with hemophilia A will enhance to overcome ...
Understanding the needs of people with hemophilia A will enhance to overcome ...Understanding the needs of people with hemophilia A will enhance to overcome ...
Understanding the needs of people with hemophilia A will enhance to overcome ...
Aleksandar Smokovski, MD
 
69420 145729-1-pb
69420 145729-1-pb69420 145729-1-pb
69420 145729-1-pb
smuchai82
 
Depresion y vih rep2014
Depresion y vih rep2014Depresion y vih rep2014
Depresion y vih rep2014
Rosa Alcayaga
 
Cancer as a causes of death among people with aids
Cancer as a causes of death among people with aidsCancer as a causes of death among people with aids
Cancer as a causes of death among people with aids
Ana Paula Bringel
 
Global death causes & preventive strategy
Global death causes & preventive strategyGlobal death causes & preventive strategy
Global death causes & preventive strategy
DeepikaHarish
 
A less-invasive-approach-of-medial-meniscectomy-in-rat-a-model-to-target-earl...
A less-invasive-approach-of-medial-meniscectomy-in-rat-a-model-to-target-earl...A less-invasive-approach-of-medial-meniscectomy-in-rat-a-model-to-target-earl...
A less-invasive-approach-of-medial-meniscectomy-in-rat-a-model-to-target-earl...
science journals
 
Ms cs for_critically_ill_covid-19_patients.pdf
Ms cs for_critically_ill_covid-19_patients.pdfMs cs for_critically_ill_covid-19_patients.pdf
Ms cs for_critically_ill_covid-19_patients.pdf
ComprehensiveBiologi
 
Death By Medicine
Death By MedicineDeath By Medicine
Death By Medicine
Ray Gebauer
 
Aids cure research_for_everyone
Aids cure research_for_everyoneAids cure research_for_everyone
Aids cure research_for_everyone
ssegujja silvest silver
 
The case for Genomic Medicine, (Personalized, Individualized Medicine). Medic...
The case for Genomic Medicine, (Personalized, Individualized Medicine). Medic...The case for Genomic Medicine, (Personalized, Individualized Medicine). Medic...
The case for Genomic Medicine, (Personalized, Individualized Medicine). Medic...
Mathura Shanmugasundaram PhD
 
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
gpartha85
 
Meghaan Walsh HJS Poster[1]
Meghaan Walsh HJS Poster[1]Meghaan Walsh HJS Poster[1]
Meghaan Walsh HJS Poster[1]
Mary Beth Levin
 
COVID-19 DATABASE Dr. Freddy Flores Malpartida
COVID-19 DATABASE Dr. Freddy Flores MalpartidaCOVID-19 DATABASE Dr. Freddy Flores Malpartida
COVID-19 DATABASE Dr. Freddy Flores Malpartida
Freddy Flores Malpartida
 
FirstLine Therapy. Prevent chronic Disease
FirstLine Therapy. Prevent chronic DiseaseFirstLine Therapy. Prevent chronic Disease
FirstLine Therapy. Prevent chronic Disease
adj4god
 
Heart Disease Analysis System
Heart Disease Analysis SystemHeart Disease Analysis System
Heart Disease Analysis System
ijtsrd
 
Bryan_Stuart_MRPPoster3
Bryan_Stuart_MRPPoster3Bryan_Stuart_MRPPoster3
Bryan_Stuart_MRPPoster3
Bryan Stuart
 
Physician Dispensing
Physician DispensingPhysician Dispensing
Physician Dispensing
dispensingphysician
 
July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?
July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?
July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?
Canadian Organization for Rare Disorders
 

What's hot (19)

Adherencia al tarv en am latina y caribe
Adherencia al tarv en am latina y caribeAdherencia al tarv en am latina y caribe
Adherencia al tarv en am latina y caribe
 
Understanding the needs of people with hemophilia A will enhance to overcome ...
Understanding the needs of people with hemophilia A will enhance to overcome ...Understanding the needs of people with hemophilia A will enhance to overcome ...
Understanding the needs of people with hemophilia A will enhance to overcome ...
 
69420 145729-1-pb
69420 145729-1-pb69420 145729-1-pb
69420 145729-1-pb
 
Depresion y vih rep2014
Depresion y vih rep2014Depresion y vih rep2014
Depresion y vih rep2014
 
Cancer as a causes of death among people with aids
Cancer as a causes of death among people with aidsCancer as a causes of death among people with aids
Cancer as a causes of death among people with aids
 
Global death causes & preventive strategy
Global death causes & preventive strategyGlobal death causes & preventive strategy
Global death causes & preventive strategy
 
A less-invasive-approach-of-medial-meniscectomy-in-rat-a-model-to-target-earl...
A less-invasive-approach-of-medial-meniscectomy-in-rat-a-model-to-target-earl...A less-invasive-approach-of-medial-meniscectomy-in-rat-a-model-to-target-earl...
A less-invasive-approach-of-medial-meniscectomy-in-rat-a-model-to-target-earl...
 
Ms cs for_critically_ill_covid-19_patients.pdf
Ms cs for_critically_ill_covid-19_patients.pdfMs cs for_critically_ill_covid-19_patients.pdf
Ms cs for_critically_ill_covid-19_patients.pdf
 
Death By Medicine
Death By MedicineDeath By Medicine
Death By Medicine
 
Aids cure research_for_everyone
Aids cure research_for_everyoneAids cure research_for_everyone
Aids cure research_for_everyone
 
The case for Genomic Medicine, (Personalized, Individualized Medicine). Medic...
The case for Genomic Medicine, (Personalized, Individualized Medicine). Medic...The case for Genomic Medicine, (Personalized, Individualized Medicine). Medic...
The case for Genomic Medicine, (Personalized, Individualized Medicine). Medic...
 
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
Predicting Trends in Preventive Care Service Utilization Impacting Cardiovasc...
 
Meghaan Walsh HJS Poster[1]
Meghaan Walsh HJS Poster[1]Meghaan Walsh HJS Poster[1]
Meghaan Walsh HJS Poster[1]
 
COVID-19 DATABASE Dr. Freddy Flores Malpartida
COVID-19 DATABASE Dr. Freddy Flores MalpartidaCOVID-19 DATABASE Dr. Freddy Flores Malpartida
COVID-19 DATABASE Dr. Freddy Flores Malpartida
 
FirstLine Therapy. Prevent chronic Disease
FirstLine Therapy. Prevent chronic DiseaseFirstLine Therapy. Prevent chronic Disease
FirstLine Therapy. Prevent chronic Disease
 
Heart Disease Analysis System
Heart Disease Analysis SystemHeart Disease Analysis System
Heart Disease Analysis System
 
Bryan_Stuart_MRPPoster3
Bryan_Stuart_MRPPoster3Bryan_Stuart_MRPPoster3
Bryan_Stuart_MRPPoster3
 
Physician Dispensing
Physician DispensingPhysician Dispensing
Physician Dispensing
 
July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?
July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?
July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?
 

Viewers also liked

STEM: Building a 21st Century Workforce to Develop Tomorrow's New Medicines
STEM: Building a 21st Century Workforce to Develop Tomorrow's New MedicinesSTEM: Building a 21st Century Workforce to Develop Tomorrow's New Medicines
STEM: Building a 21st Century Workforce to Develop Tomorrow's New Medicines
PhRMA
 
2014 Report: Medicines in Development for Arthritis
2014 Report: Medicines in Development for Arthritis2014 Report: Medicines in Development for Arthritis
2014 Report: Medicines in Development for Arthritis
PhRMA
 
PhRMA STEM Education Factsheet 2014
PhRMA STEM Education Factsheet 2014PhRMA STEM Education Factsheet 2014
PhRMA STEM Education Factsheet 2014
PhRMA
 
Social Media Report - Household Cleaning Products October-November 2016
Social Media Report - Household Cleaning Products October-November 2016Social Media Report - Household Cleaning Products October-November 2016
Social Media Report - Household Cleaning Products October-November 2016
Unmetric
 
2014 Profile: Biopharmaceutical Research Industry
2014 Profile: Biopharmaceutical Research Industry2014 Profile: Biopharmaceutical Research Industry
2014 Profile: Biopharmaceutical Research Industry
PhRMA
 
Videogames Industry in Russia 2014
Videogames Industry in Russia 2014Videogames Industry in Russia 2014
Videogames Industry in Russia 2014
Andrey Podshibyakin
 
Исследование авторынка России в социальных сетях
Исследование авторынка России в социальных сетяхИсследование авторынка России в социальных сетях
Исследование авторынка России в социальных сетях
Real Time Agency
 
E-mail маркетинг в России: обзор и руководство к действию_ by E-commerce Fitn...
E-mail маркетинг в России: обзор и руководство к действию_ by E-commerce Fitn...E-mail маркетинг в России: обзор и руководство к действию_ by E-commerce Fitn...
E-mail маркетинг в России: обзор и руководство к действию_ by E-commerce Fitn...Efim Aldoukhov
 
Medical Cost Trend: Behind the Numbers 2017
Medical Cost Trend: Behind the Numbers 2017Medical Cost Trend: Behind the Numbers 2017
Medical Cost Trend: Behind the Numbers 2017
PwC
 
Российская аудитория социальных сетей апрель 2014
Российская аудитория социальных сетей апрель 2014Российская аудитория социальных сетей апрель 2014
Российская аудитория социальных сетей апрель 2014
Angel Relations Group
 
Cold, Cough, Flu Shopper Insights [SURVEY]
Cold, Cough, Flu Shopper Insights [SURVEY]Cold, Cough, Flu Shopper Insights [SURVEY]
Cold, Cough, Flu Shopper Insights [SURVEY]
Field Agent
 
Обзор рынка онлайн-видео Рунета (2013)
Обзор рынка онлайн-видео Рунета (2013)Обзор рынка онлайн-видео Рунета (2013)
Обзор рынка онлайн-видео Рунета (2013)
Affect Digital
 
Findings on health information technology and electronic health records
Findings on health information technology and electronic health recordsFindings on health information technology and electronic health records
Findings on health information technology and electronic health records
Deloitte United States
 
Social media report - Automobile Brands January 1st - December 31st 2016
Social media report  - Automobile Brands January 1st - December 31st 2016Social media report  - Automobile Brands January 1st - December 31st 2016
Social media report - Automobile Brands January 1st - December 31st 2016
Unmetric
 
2017 Top Issues - Changing Business Models - January 2017
2017 Top Issues -  Changing Business Models  - January 20172017 Top Issues -  Changing Business Models  - January 2017
2017 Top Issues - Changing Business Models - January 2017
PwC
 
2017 Top Issues - Financial Reporting Modernization - January 2017
2017 Top Issues - Financial Reporting Modernization - January 20172017 Top Issues - Financial Reporting Modernization - January 2017
2017 Top Issues - Financial Reporting Modernization - January 2017
PwC
 
Что такое аналитика в маркетинге, зачем она нужна, и как ее готовить
Что такое аналитика в маркетинге, зачем она нужна, и как ее готовитьЧто такое аналитика в маркетинге, зачем она нужна, и как ее готовить
Что такое аналитика в маркетинге, зачем она нужна, и как ее готовить
Mindbox
 
Prescription Medicines: Costs in Context
Prescription Medicines: Costs in Context Prescription Medicines: Costs in Context
Prescription Medicines: Costs in Context
PhRMA
 
TMT Outlook 2017: A new wave of advances offer opportunities and challenges
TMT Outlook 2017:  A new wave of advances offer opportunities and challengesTMT Outlook 2017:  A new wave of advances offer opportunities and challenges
TMT Outlook 2017: A new wave of advances offer opportunities and challenges
Deloitte United States
 

Viewers also liked (19)

STEM: Building a 21st Century Workforce to Develop Tomorrow's New Medicines
STEM: Building a 21st Century Workforce to Develop Tomorrow's New MedicinesSTEM: Building a 21st Century Workforce to Develop Tomorrow's New Medicines
STEM: Building a 21st Century Workforce to Develop Tomorrow's New Medicines
 
2014 Report: Medicines in Development for Arthritis
2014 Report: Medicines in Development for Arthritis2014 Report: Medicines in Development for Arthritis
2014 Report: Medicines in Development for Arthritis
 
PhRMA STEM Education Factsheet 2014
PhRMA STEM Education Factsheet 2014PhRMA STEM Education Factsheet 2014
PhRMA STEM Education Factsheet 2014
 
Social Media Report - Household Cleaning Products October-November 2016
Social Media Report - Household Cleaning Products October-November 2016Social Media Report - Household Cleaning Products October-November 2016
Social Media Report - Household Cleaning Products October-November 2016
 
2014 Profile: Biopharmaceutical Research Industry
2014 Profile: Biopharmaceutical Research Industry2014 Profile: Biopharmaceutical Research Industry
2014 Profile: Biopharmaceutical Research Industry
 
Videogames Industry in Russia 2014
Videogames Industry in Russia 2014Videogames Industry in Russia 2014
Videogames Industry in Russia 2014
 
Исследование авторынка России в социальных сетях
Исследование авторынка России в социальных сетяхИсследование авторынка России в социальных сетях
Исследование авторынка России в социальных сетях
 
E-mail маркетинг в России: обзор и руководство к действию_ by E-commerce Fitn...
E-mail маркетинг в России: обзор и руководство к действию_ by E-commerce Fitn...E-mail маркетинг в России: обзор и руководство к действию_ by E-commerce Fitn...
E-mail маркетинг в России: обзор и руководство к действию_ by E-commerce Fitn...
 
Medical Cost Trend: Behind the Numbers 2017
Medical Cost Trend: Behind the Numbers 2017Medical Cost Trend: Behind the Numbers 2017
Medical Cost Trend: Behind the Numbers 2017
 
Российская аудитория социальных сетей апрель 2014
Российская аудитория социальных сетей апрель 2014Российская аудитория социальных сетей апрель 2014
Российская аудитория социальных сетей апрель 2014
 
Cold, Cough, Flu Shopper Insights [SURVEY]
Cold, Cough, Flu Shopper Insights [SURVEY]Cold, Cough, Flu Shopper Insights [SURVEY]
Cold, Cough, Flu Shopper Insights [SURVEY]
 
Обзор рынка онлайн-видео Рунета (2013)
Обзор рынка онлайн-видео Рунета (2013)Обзор рынка онлайн-видео Рунета (2013)
Обзор рынка онлайн-видео Рунета (2013)
 
Findings on health information technology and electronic health records
Findings on health information technology and electronic health recordsFindings on health information technology and electronic health records
Findings on health information technology and electronic health records
 
Social media report - Automobile Brands January 1st - December 31st 2016
Social media report  - Automobile Brands January 1st - December 31st 2016Social media report  - Automobile Brands January 1st - December 31st 2016
Social media report - Automobile Brands January 1st - December 31st 2016
 
2017 Top Issues - Changing Business Models - January 2017
2017 Top Issues -  Changing Business Models  - January 20172017 Top Issues -  Changing Business Models  - January 2017
2017 Top Issues - Changing Business Models - January 2017
 
2017 Top Issues - Financial Reporting Modernization - January 2017
2017 Top Issues - Financial Reporting Modernization - January 20172017 Top Issues - Financial Reporting Modernization - January 2017
2017 Top Issues - Financial Reporting Modernization - January 2017
 
Что такое аналитика в маркетинге, зачем она нужна, и как ее готовить
Что такое аналитика в маркетинге, зачем она нужна, и как ее готовитьЧто такое аналитика в маркетинге, зачем она нужна, и как ее готовить
Что такое аналитика в маркетинге, зачем она нужна, и как ее готовить
 
Prescription Medicines: Costs in Context
Prescription Medicines: Costs in Context Prescription Medicines: Costs in Context
Prescription Medicines: Costs in Context
 
TMT Outlook 2017: A new wave of advances offer opportunities and challenges
TMT Outlook 2017:  A new wave of advances offer opportunities and challengesTMT Outlook 2017:  A new wave of advances offer opportunities and challenges
TMT Outlook 2017: A new wave of advances offer opportunities and challenges
 

Similar to 2014 Report: Medicines in Development for HIV/AIDS

Learning from aids pandemic ...
Learning from aids pandemic                                                  ...Learning from aids pandemic                                                  ...
Learning from aids pandemic ...
Society for Microbiology and Infection care
 
A basic understanding of HIV surveillance
A basic understanding of HIV surveillanceA basic understanding of HIV surveillance
A basic understanding of HIV surveillance
Dr.RAJEEV KASHYAP
 
HIV vaccines
HIV vaccinesHIV vaccines
HIV vaccines
guest48a4528
 
Sas overview logo
Sas overview logoSas overview logo
Sas overview logo
Emily Winkelstein
 
At Risk? Vaccinate Now! A National Campaign for Those 50 years and Older in ...
At Risk? Vaccinate Now!  A National Campaign for Those 50 years and Older in ...At Risk? Vaccinate Now!  A National Campaign for Those 50 years and Older in ...
At Risk? Vaccinate Now! A National Campaign for Those 50 years and Older in ...
Angel Hernández
 
Hiv vaccine market opportunity & clinical pipeline analysis
Hiv vaccine market opportunity & clinical pipeline analysisHiv vaccine market opportunity & clinical pipeline analysis
Hiv vaccine market opportunity & clinical pipeline analysis
KuicK Research
 
CDC AR Threats Report'2019 - Key Highlights
CDC AR Threats Report'2019 - Key HighlightsCDC AR Threats Report'2019 - Key Highlights
CDC AR Threats Report'2019 - Key Highlights
TeamZevac
 
Crimson Publishers-Pre-Exposure Prophylaxis for HIV Infection, is it Working?
Crimson Publishers-Pre-Exposure Prophylaxis for HIV Infection, is it Working? Crimson Publishers-Pre-Exposure Prophylaxis for HIV Infection, is it Working?
Crimson Publishers-Pre-Exposure Prophylaxis for HIV Infection, is it Working?
CrimsonPublishers-PRM
 
A platform technology to address bioterrorism
A platform technology to address bioterrorismA platform technology to address bioterrorism
A platform technology to address bioterrorism
Aethlon Medical, Inc.
 
HIV UPDATE TREATMENT
HIV UPDATE TREATMENTHIV UPDATE TREATMENT
HIV UPDATE TREATMENT
rafa64
 
Piis074937970300120 x
Piis074937970300120 xPiis074937970300120 x
Piis074937970300120 x
Luis Carlos Murillo Valencia
 
Hiv Essay
Hiv EssayHiv Essay
Hiv Essay
Emily Jones
 
A new options for hiv prevention slides.2013
A new options for hiv prevention slides.2013A new options for hiv prevention slides.2013
A new options for hiv prevention slides.2013
Hivlife Info
 
04.03.20 | COVID-19 and HIV: What We Know and Efforts to Answer What We Don’t...
04.03.20 | COVID-19 and HIV: What We Know and Efforts to Answer What We Don’t...04.03.20 | COVID-19 and HIV: What We Know and Efforts to Answer What We Don’t...
04.03.20 | COVID-19 and HIV: What We Know and Efforts to Answer What We Don’t...
UC San Diego AntiViral Research Center
 
Vaccine Truth
Vaccine TruthVaccine Truth
Vaccine Truth
John Bergman
 
Vaccination2014 150420100600-conversion-gate02
Vaccination2014 150420100600-conversion-gate02Vaccination2014 150420100600-conversion-gate02
Vaccination2014 150420100600-conversion-gate02
Marly0710
 
Resistencia antimicroviana
Resistencia antimicrovianaResistencia antimicroviana
Resistencia antimicroviana
Lic en Enfermeria Zamudio
 
HIV:AIDS-Latino
HIV:AIDS-LatinoHIV:AIDS-Latino
HIV:AIDS-Latino
Elena Kennedy
 
Management of patient with AIDS
Management of patient with AIDSManagement of patient with AIDS
Management of patient with AIDS
Mathew Varghese V
 
Global Medical Cures™ | HIV TESTING IN USA
Global Medical Cures™ | HIV TESTING IN USAGlobal Medical Cures™ | HIV TESTING IN USA
Global Medical Cures™ | HIV TESTING IN USA
Global Medical Cures™
 

Similar to 2014 Report: Medicines in Development for HIV/AIDS (20)

Learning from aids pandemic ...
Learning from aids pandemic                                                  ...Learning from aids pandemic                                                  ...
Learning from aids pandemic ...
 
A basic understanding of HIV surveillance
A basic understanding of HIV surveillanceA basic understanding of HIV surveillance
A basic understanding of HIV surveillance
 
HIV vaccines
HIV vaccinesHIV vaccines
HIV vaccines
 
Sas overview logo
Sas overview logoSas overview logo
Sas overview logo
 
At Risk? Vaccinate Now! A National Campaign for Those 50 years and Older in ...
At Risk? Vaccinate Now!  A National Campaign for Those 50 years and Older in ...At Risk? Vaccinate Now!  A National Campaign for Those 50 years and Older in ...
At Risk? Vaccinate Now! A National Campaign for Those 50 years and Older in ...
 
Hiv vaccine market opportunity & clinical pipeline analysis
Hiv vaccine market opportunity & clinical pipeline analysisHiv vaccine market opportunity & clinical pipeline analysis
Hiv vaccine market opportunity & clinical pipeline analysis
 
CDC AR Threats Report'2019 - Key Highlights
CDC AR Threats Report'2019 - Key HighlightsCDC AR Threats Report'2019 - Key Highlights
CDC AR Threats Report'2019 - Key Highlights
 
Crimson Publishers-Pre-Exposure Prophylaxis for HIV Infection, is it Working?
Crimson Publishers-Pre-Exposure Prophylaxis for HIV Infection, is it Working? Crimson Publishers-Pre-Exposure Prophylaxis for HIV Infection, is it Working?
Crimson Publishers-Pre-Exposure Prophylaxis for HIV Infection, is it Working?
 
A platform technology to address bioterrorism
A platform technology to address bioterrorismA platform technology to address bioterrorism
A platform technology to address bioterrorism
 
HIV UPDATE TREATMENT
HIV UPDATE TREATMENTHIV UPDATE TREATMENT
HIV UPDATE TREATMENT
 
Piis074937970300120 x
Piis074937970300120 xPiis074937970300120 x
Piis074937970300120 x
 
Hiv Essay
Hiv EssayHiv Essay
Hiv Essay
 
A new options for hiv prevention slides.2013
A new options for hiv prevention slides.2013A new options for hiv prevention slides.2013
A new options for hiv prevention slides.2013
 
04.03.20 | COVID-19 and HIV: What We Know and Efforts to Answer What We Don’t...
04.03.20 | COVID-19 and HIV: What We Know and Efforts to Answer What We Don’t...04.03.20 | COVID-19 and HIV: What We Know and Efforts to Answer What We Don’t...
04.03.20 | COVID-19 and HIV: What We Know and Efforts to Answer What We Don’t...
 
Vaccine Truth
Vaccine TruthVaccine Truth
Vaccine Truth
 
Vaccination2014 150420100600-conversion-gate02
Vaccination2014 150420100600-conversion-gate02Vaccination2014 150420100600-conversion-gate02
Vaccination2014 150420100600-conversion-gate02
 
Resistencia antimicroviana
Resistencia antimicrovianaResistencia antimicroviana
Resistencia antimicroviana
 
HIV:AIDS-Latino
HIV:AIDS-LatinoHIV:AIDS-Latino
HIV:AIDS-Latino
 
Management of patient with AIDS
Management of patient with AIDSManagement of patient with AIDS
Management of patient with AIDS
 
Global Medical Cures™ | HIV TESTING IN USA
Global Medical Cures™ | HIV TESTING IN USAGlobal Medical Cures™ | HIV TESTING IN USA
Global Medical Cures™ | HIV TESTING IN USA
 

More from PhRMA

Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
PhRMA
 
Prescription Medicines: Costs in Context - May 2023
Prescription Medicines: Costs in Context - May 2023Prescription Medicines: Costs in Context - May 2023
Prescription Medicines: Costs in Context - May 2023
PhRMA
 
Prescription Medicines: Costs in Context - August2022
Prescription Medicines: Costs in Context - August2022Prescription Medicines: Costs in Context - August2022
Prescription Medicines: Costs in Context - August2022
PhRMA
 
Prescription Medicines: Costs in Context - June 2022
Prescription Medicines: Costs in Context - June 2022Prescription Medicines: Costs in Context - June 2022
Prescription Medicines: Costs in Context - June 2022
PhRMA
 
Prescription Medicines: Costs in Context June 2022
Prescription Medicines: Costs in Context June 2022Prescription Medicines: Costs in Context June 2022
Prescription Medicines: Costs in Context June 2022
PhRMA
 
Prescription Medicines Insulin Costs in Context May 2022
Prescription Medicines Insulin Costs in Context May 2022Prescription Medicines Insulin Costs in Context May 2022
Prescription Medicines Insulin Costs in Context May 2022
PhRMA
 
Prescription Medicines Costs in Context April 2022
Prescription Medicines Costs in Context April 2022Prescription Medicines Costs in Context April 2022
Prescription Medicines Costs in Context April 2022
PhRMA
 
Prescription Medicines Costs in Context March 2022
Prescription Medicines Costs in Context March 2022Prescription Medicines Costs in Context March 2022
Prescription Medicines Costs in Context March 2022
PhRMA
 
Prescription Medicines Costs in Context July 2021
Prescription Medicines Costs in Context July 2021Prescription Medicines Costs in Context July 2021
Prescription Medicines Costs in Context July 2021
PhRMA
 
Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021
PhRMA
 
Prescription Medicines Insulin Costs in Context en Español February 2021
Prescription Medicines Insulin Costs in Context en Español February 2021Prescription Medicines Insulin Costs in Context en Español February 2021
Prescription Medicines Insulin Costs in Context en Español February 2021
PhRMA
 
Prescription Medicines: Insulin Costs in Context January 2021
Prescription Medicines: Insulin Costs in Context January 2021Prescription Medicines: Insulin Costs in Context January 2021
Prescription Medicines: Insulin Costs in Context January 2021
PhRMA
 
Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020
PhRMA
 
Prescription Medicines Costs in Context May 2020
Prescription Medicines Costs in Context May 2020Prescription Medicines Costs in Context May 2020
Prescription Medicines Costs in Context May 2020
PhRMA
 
Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020
PhRMA
 
Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019
PhRMA
 
Prescription Medicines Insulin Costs in Context en Español June 2019
Prescription Medicines Insulin Costs in Context en Español June 2019Prescription Medicines Insulin Costs in Context en Español June 2019
Prescription Medicines Insulin Costs in Context en Español June 2019
PhRMA
 
Prescription Medicines Insulin Costs in Context June 2019
Prescription Medicines Insulin Costs in Context June 2019Prescription Medicines Insulin Costs in Context June 2019
Prescription Medicines Insulin Costs in Context June 2019
PhRMA
 
Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019
PhRMA
 
Prescription Medicines - Insulin Costs in Context
Prescription Medicines - Insulin Costs in ContextPrescription Medicines - Insulin Costs in Context
Prescription Medicines - Insulin Costs in Context
PhRMA
 

More from PhRMA (20)

Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
 
Prescription Medicines: Costs in Context - May 2023
Prescription Medicines: Costs in Context - May 2023Prescription Medicines: Costs in Context - May 2023
Prescription Medicines: Costs in Context - May 2023
 
Prescription Medicines: Costs in Context - August2022
Prescription Medicines: Costs in Context - August2022Prescription Medicines: Costs in Context - August2022
Prescription Medicines: Costs in Context - August2022
 
Prescription Medicines: Costs in Context - June 2022
Prescription Medicines: Costs in Context - June 2022Prescription Medicines: Costs in Context - June 2022
Prescription Medicines: Costs in Context - June 2022
 
Prescription Medicines: Costs in Context June 2022
Prescription Medicines: Costs in Context June 2022Prescription Medicines: Costs in Context June 2022
Prescription Medicines: Costs in Context June 2022
 
Prescription Medicines Insulin Costs in Context May 2022
Prescription Medicines Insulin Costs in Context May 2022Prescription Medicines Insulin Costs in Context May 2022
Prescription Medicines Insulin Costs in Context May 2022
 
Prescription Medicines Costs in Context April 2022
Prescription Medicines Costs in Context April 2022Prescription Medicines Costs in Context April 2022
Prescription Medicines Costs in Context April 2022
 
Prescription Medicines Costs in Context March 2022
Prescription Medicines Costs in Context March 2022Prescription Medicines Costs in Context March 2022
Prescription Medicines Costs in Context March 2022
 
Prescription Medicines Costs in Context July 2021
Prescription Medicines Costs in Context July 2021Prescription Medicines Costs in Context July 2021
Prescription Medicines Costs in Context July 2021
 
Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021
 
Prescription Medicines Insulin Costs in Context en Español February 2021
Prescription Medicines Insulin Costs in Context en Español February 2021Prescription Medicines Insulin Costs in Context en Español February 2021
Prescription Medicines Insulin Costs in Context en Español February 2021
 
Prescription Medicines: Insulin Costs in Context January 2021
Prescription Medicines: Insulin Costs in Context January 2021Prescription Medicines: Insulin Costs in Context January 2021
Prescription Medicines: Insulin Costs in Context January 2021
 
Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020
 
Prescription Medicines Costs in Context May 2020
Prescription Medicines Costs in Context May 2020Prescription Medicines Costs in Context May 2020
Prescription Medicines Costs in Context May 2020
 
Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020
 
Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019
 
Prescription Medicines Insulin Costs in Context en Español June 2019
Prescription Medicines Insulin Costs in Context en Español June 2019Prescription Medicines Insulin Costs in Context en Español June 2019
Prescription Medicines Insulin Costs in Context en Español June 2019
 
Prescription Medicines Insulin Costs in Context June 2019
Prescription Medicines Insulin Costs in Context June 2019Prescription Medicines Insulin Costs in Context June 2019
Prescription Medicines Insulin Costs in Context June 2019
 
Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019
 
Prescription Medicines - Insulin Costs in Context
Prescription Medicines - Insulin Costs in ContextPrescription Medicines - Insulin Costs in Context
Prescription Medicines - Insulin Costs in Context
 

Recently uploaded

pharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdfpharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdf
KerlynIgnacio
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
Jim Jacob Roy
 
Skin Diseases That Happen During Summer.
 Skin Diseases That Happen During Summer. Skin Diseases That Happen During Summer.
Skin Diseases That Happen During Summer.
Gokuldas Hospital
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Call Girls In Mumbai +91-7426014248 High Profile Call Girl MumbaiCall Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Mobile Problem
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
DrGirishJHoogar
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticalsacne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
MuskanShingari
 
Foundation of Yoga, YCB Level-3, Unit-1
Foundation of Yoga, YCB Level-3, Unit-1 Foundation of Yoga, YCB Level-3, Unit-1
Foundation of Yoga, YCB Level-3, Unit-1
Jyoti Bhaghasra
 
Local anesthetics 2024/ Medicinal Chemistry pdf
Local anesthetics 2024/ Medicinal Chemistry pdfLocal anesthetics 2024/ Medicinal Chemistry pdf
Local anesthetics 2024/ Medicinal Chemistry pdf
NarminHamaaminHussen
 
Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.
Gokuldas Hospital
 
Breast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapyBreast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapy
Dr. Sumit KUMAR
 
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga
 
biomechanics of running. Dr.dhwani.pptx
biomechanics of running.   Dr.dhwani.pptxbiomechanics of running.   Dr.dhwani.pptx
biomechanics of running. Dr.dhwani.pptx
Dr. Dhwani kawedia
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
phuakl
 
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
NX Healthcare
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 
What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?
Healthmedsrx.com
 

Recently uploaded (20)

pharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdfpharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdf
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
 
Skin Diseases That Happen During Summer.
 Skin Diseases That Happen During Summer. Skin Diseases That Happen During Summer.
Skin Diseases That Happen During Summer.
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Call Girls In Mumbai +91-7426014248 High Profile Call Girl MumbaiCall Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticalsacne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
 
Foundation of Yoga, YCB Level-3, Unit-1
Foundation of Yoga, YCB Level-3, Unit-1 Foundation of Yoga, YCB Level-3, Unit-1
Foundation of Yoga, YCB Level-3, Unit-1
 
Local anesthetics 2024/ Medicinal Chemistry pdf
Local anesthetics 2024/ Medicinal Chemistry pdfLocal anesthetics 2024/ Medicinal Chemistry pdf
Local anesthetics 2024/ Medicinal Chemistry pdf
 
Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.
 
Breast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapyBreast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapy
 
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
 
biomechanics of running. Dr.dhwani.pptx
biomechanics of running.   Dr.dhwani.pptxbiomechanics of running.   Dr.dhwani.pptx
biomechanics of running. Dr.dhwani.pptx
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
 
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 
What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?What is Obesity? How to overcome Obesity?
What is Obesity? How to overcome Obesity?
 

2014 Report: Medicines in Development for HIV/AIDS

  • 1. 2014 REPORT PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Company Researchers Are Developing More Than 40 Medicines and Vaccines For HIV Infection Treatment and Prevention Globally, approximately 35 million people are infected with human immunodefi - ciency virus (HIV), the virus that causes acquired immune defi ciency syndrome (AIDS). However, new infections have dropped by 38 percent since 2001, according to UNAIDS, the Joint United Nations Programme on HIV/AIDS. In the United States, more than 1.1 million people are living with HIV and 15.8 percent of those are unaware they are infected, according to the U.S. Centers for Disease Control and Prevention (CDC). Although the U.S. HIV/AIDS-related death rate has fallen by more than 80 percent since the introduction of antiretroviral therapies in 1995, new HIV infections have stabilized at approximately 50,000 each year, according to the CDC. Since AIDS was fi rst reported in 1981, nearly 40 medicines have been approved to treat HIV infection in the United States. Although those medicines have made HIV infection a manageable chronic disease and helped to prolong the lives of infected patients, opportunities for even greater progress remain. Biopharmaceutical research companies are developing 44 medicines and vaccines for HIV infection, focusing on improved treatment regimens, more effective therapies, and preventative vaccines. These medicines and vaccines are either in clinical trials or awaiting review by the U.S. Food and Drug Administration (FDA). The 44 medicines and vaccines in the development pipeline include: • A fi rst-in-class medicine intended to prevent HIV from breaking through the cell membrane. • A cell therapy that modifi es a patient’s own cells in an attempt to make them resistant to HIV. MEDICINES IN DEVELOPMENT HIV/AIDS Medicines and Vaccines in Development for HIV Infection 25 Antivirals Cell/Gene Therapy Vaccines 3 16 Application Submitted Phase III Phase II Phase I Some medicines are listed in more than one category. Contents HIV Medicines and Vaccines in Development ......................................2 Incremental Innovation in HIV/AIDS Treatment .......................... 4 Access to HIV/AIDS Medicines in Exchange Plans ...................................5 Facts About HIV/AIDS ........................7 Medicines and Vaccines in Development Chart ............................ 8 Approved Medicines for HIV/AIDS ................................... 13 The Drug Discovery, Development and Approval Process ........................ 15
  • 2. Key Issues • A therapeutic vaccine designed to induce responses from T cells that play a role in immune protection against viral infections. The development of new, innovative therapies would not be possible without the patients who volunteer to participate in clinical trials. Currently, there are 94 active clinical trials for HIV infection medicines and vaccines in the United States. Of those, 43 have not yet started recruiting patients or have just begun to seek volunteers to participate; the other 51 are ongoing but not recruiting new patients.* Researching and developing new medicines remains a risky investment and a lengthy process. On average, it costs $1.2 billion and takes between 10–15 years to bring a new medicine to patients. Despite the risks, America’s biopharmaceutical research companies are continuing their efforts to develop novel and more effective treatments, vaccines to prevent HIV infection, and potentially a cure. HIV Medicines and Vaccines in Development Biopharmaceutical research companies are investigating new ways to treat and prevent HIV infection. Potential therapies being developed for HIV infection include: HIV/AIDS IN THE UNITED STATES 44 MEDICINES & VACCINES IN DEVELOPMENT for HIV infection 25 Antivirals 3 16 Cell/Gene Therapy Source: 2014 PhRMA Medicines in Development for HIV/AIDS, PhRMA. Vaccines Attachment Inhibitor—A new class of HIV medicines is intended to protect cells from HIV infection by preventing the virus from attaching to new cells and breaking through the cell membrane. One attachment inhibitor in development attaches to gp120, a part of the virus, and inhibits the entry of the virus into cells by blocking the interaction between gp120 and the cell receptors. Gene Modifi cation—CCR5 is a co-receptor on the surface of cells that allows HIV to enter and infect T cells. Without this receptor on the cell surface, it is more diffi cult for HIV to infect the cells. One cell therapy currently in clinical trials is designed to modify the DNA sequence encoding CCR5 with the intent of making the patient’s own cells resistant to infection by HIV. The patient’s cells are extracted, modifi ed, and then reinserted into the patient. The goal of this therapy is to provide the patient with a population of cells that can fi ght HIV as well as the opportunistic infections from which patients with HIV often suffer. Inducing T Cell Responses—Another therapeutic vaccine in development is designed to induce CD4+ T cell responses in HIV-infected people. CD4+ T cells play a key role in immune protection against viral infections. Defi cits in CD4+ T cells are associated with virus reactivation, vulnerability to opportunistic infections, and poor vaccine effi cacy. HIV/AIDS IN THE UNITED STATES >1.1 MILLION living with HIV infection PLUS APPROXIMATELY NEW HIV INFECTIONS ANNUALLY Source: U.S. Centers for Disease Control and Prevention (CDC). 50,000 *Source: www.clinicaltrials.gov, search performed 8/5/2014. Search criteria: HIV infection, United States, Phase 0, 1, 2, 3; industry only. 2 Medicines in Development HIV/AIDS 2014
  • 3. Key Issues 2014 RESEARCH & HOPE AWARDS The PhRMA Research & Hope Awards recognize advances made across a critical disease or health condition by individuals or organizations in the biopharmaceutical sector, academia, government, and provider and patient organizations. On September 10, 2014, PhRMA, along with distinguished members of the medical, patient and provider communities, presented the third annual Research & Hope Awards. This year’s program honored innovators in the area of HIV/AIDS, including recent advances in the prevention and treatment of the disease. Within the “Excellence in Research” categories, honorees represented the spectrum of the ecosystem—scientists working in academic research institutions, biopharmaceutical research companies, and patient organizations. Awardees included: THE RESEARCH & HOPE AWARD FOR ACADEMIC RESEARCH This award is presented to individuals or a team from an academic institution for outstanding research in the area of HIV/AIDS. 2014 Award presented to: Raymond F. Schinazi, Ph.D., Hon. D.Sc., Emory University THE RESEARCH & HOPE AWARD FOR BIOPHARMACEUTICAL INDUSTRY RESEARCH This award is presented to individuals or a team from a biopharmaceutical company for outstanding research in the area of HIV/AIDS. 2014 Award presented to: Bristol-Myers Squibb Virology Team Dennis Michael Grasela, Pharm.D., Ph.D.; George Hanna, M.D.; John F. Kadow, Ph.D.; Mark Krystal, Ph.D.; Nick A. Meanwell, Ph.D. THE RESEARCH & HOPE AWARD FOR PATIENT AND COMMUNITY HEALTH This award is presented to an individual or organization that has had a signifi cant impact educating patients and health care providers about the importance of treatment and prevention against HIV infection in their community. 2014 “Visibility and Progress” Award presented to: Hydeia Broadbent 2014 “Community Champion” Award presented to: Kathie Hiers, AIDS Alabama 2014 “Excellence in Advocacy and Activism” Award presented to: Phill Wilson, Black AIDS Institute To learn more about the dedicated researchers honored with the 2014 Research & Hope Awards, please visit www.phrma.org/awards. Medicines in Development HIV/AIDS 2014 3
  • 4. Key Issues Incremental Innovation in HIV/AIDS Treatment Over the last two decades, research advances have transformed treatment for many patients infected with HIV. In that time, HIV/AIDS has moved from an acute, fatal illness to a chronic disease, managed by effective treatment regimens. In the United States, death rates have fallen by more than 80 percent since 1995 as a result of the development “Developing a safe and su ciently e ective HIV vaccine is essential if we are to achieve a timely and durable end to the global HIV/AIDS pandemic.” — Anthony S. Fauci, M.D., NIAID Director and introduction of multiple drugs used in innovative combinations, known as antiretroviral therapy (ART). For HIV/AIDS, the introduction of novel therapies and continuous research into their best use in patients has revealed value beyond what was known at the time of approval HIV/AIDS IN THE UNITED STATES THEN AND NOW Since HIV/AIDS was first recognized in 1981, advances in medicines have helped lower the death rate by 83%. Prior to 1995, when the first antiretroviral treatment was approved by the FDA, an HIV diagnosis was a death sentence. Now, thanks to medicines developed by biopharmaceutical scientists and their research partners, it is a chronic condition with manageable costs and patients are able to reach nearly a full life expectancy. ARTHUR ASHE Due to the lack of effective medicines, Arthur Ashe succumbed to AIDS-related pneumonia at 50 years old in 1993, just 10 years after he contracted the disease and 5 years after diagnosis Source: Magic Johnson Foundation, Arthur Ashe Learning Center (AALC). MAGIC JOHNSON Despite being diagnosed with HIV/AIDS in 1991, Magic is expected to meet his full life expectancy due to the treatments available at the outset of his diagnosis by the FDA. This value has been realized over time as new treatments build on one another and real world knowledge is accumulated. Additional post-approval value for HIV/AIDS therapies include use in combination with other therapeutics, treatment earlier in the disease state, and use to prevent HIV transmission in certain situations. PDUFA V SEEKS TO GAIN PATIENT PERSPECTIVE As part of the reauthorization of the Prescription Drug User Fee Act in 2012 (PDUFA V), FDA committed to hold 20 Patient-Focused Drug Development (PFDD) meetings on a set of disease areas in order to gain the patient perspective on disease severity and unmet medical need. In June 2013, FDA conducted a PFDD public meeting on “HIV Patient-Focused Drug Development and HIV Cure Research” to get patient input on the impact of HIV on daily life, therapies currently available to treat the infection, and patients’ views on issues related to HIV research. Consideration of patients’ perception of the acceptable balance of known and possible risks and benefi ts has the potential to add crucial perspective when regulators are faced with diffi cult benefi t-risk decisions. 4 Medicines in Development HIV/AIDS 2014
  • 5. Key Issues HIV/AIDS IN THE UNITED STATES PROGRESS IN THE FIGHT 1995: the first protease inhibitors were approved by the FDA, and the HIV/AIDS death rate decreased 67% over a few years 2006: transmission rates between mother and infant dropped below 2% Source: Magic Johnson Foundation, Arthur Ashe Learning Center (AALC). 2012: U.S. death rate dropped 83% Access to HIV/AIDS Medicines in Exchange Plans Prescription medicines are a crucial component of treatment for HIV/AIDS. Multidrug regimens have substantially reduced HIV progression to AIDS, opportunistic infections, hospitalizations, and death. Early ART regimens often required patients to take several pills multiple times a day. New formulations, such as single-tablets, reduce the patient’s pill burden dramatically, improving adherence and slowing disease progression. An analysis by Avalere Health, that was commissioned by PhRMA, offers insight into access to these medicines in the new health insurance exchanges. On average, health insurance exchange plans created by the Affordable Care Act offer HIV/AIDS medicines, but are less likely to cover combination medicines over other brand HIV/AIDS medicines. Exchange plans also impose high cost-sharing and utilization management to needed HIV/AIDS medicines. Highlights from the analysis include: • Formulary Coverage: Certain types of medicines are often excluded from the formulary. Compared to brand medicines that treat other conditions, HIV/AIDS medications are more likely to be on the formulary; however, combination therapies—which increasingly represent the standard-of-care in treatment of HIV/AIDS—are less likely than single-ingredient HIV/AIDS medications to be covered. Exchange plans cover single-source brand HIV/AIDS medicines (defi ned as medicines for which a generic equivalent is not available) 81 percent of the time, but only cover combination medicines 67 percent of the time. • Cost-Sharing: Medicines to treat HIV/AIDS are sometimes subject to high coinsurance. HIV/AIDS medicines are subject to coinsurance in approximately 55 percent of plans, with an average coinsurance of 35 percent for all medications and 37 percent for combination medicines. For a single HIV/AIDS medicine subject to a coinsurance of 35 percent, out-of-pocket costs could range from $1,100 to over $6,000 annually. HIV/AIDS IN THE UNITED STATES Frequency of COPAYMENT vs. COINSURANCE by Amount for HIV/AIDS Medicines in SILVER PLANS 19% 13% 10% 12% 46% COPAYMENT HIV/AIDS CLASSES 19% 13% 11% 8% 47% COPAYMENT COINSURANCE COMBINATION PRODUCTS 40% 31-40% 21-30% 0-20% Source: Access to HIV/AIDS Medications in Exchange Plans, PhRMA. Medicines in Development HIV/AIDS 2014 5
  • 6. Key Issues HIV/AIDS IN THE UNITED STATES Utilization Management of HIV/AIDS MEDICINES 26% 74% 8% 5% EXCHANGE PLANS 92% 95% UTILIZATION MANAGEMENT NO UTILIZATION MANAGEMENT EMPLOYER PLANS BENCHMARK PLANS Source: Access to HIV/AIDS Medications in Exchange Plans, PhRMA. • Access Limits: Medicines are more likely to be subject to utilization management—step therapy or prior authorization—in exchange plans than in employer or benchmark plans. For HIV/AIDS, utilization management is three times as likely in exchange plans compared to employer plans (26 percent compared to 8 percent of the time). PRE-EXPOSURE PROPHYLAXIS FOR AT-RISK POPULATIONS Health offi cials in the United States have recommended pre-exposure prophylaxis (PrEP) for Americans who are at risk of sexually acquired HIV infection. According to the CDC, such a prevention strategy could help decrease the estimated 50,000 new infections each year in the United States. This strategy has also been endorsed by the World Health Organization (WHO). Offi cials recommended that at-risk adult populations take Truvada® (emtricitabine and tenofovir disoproxil fumarate), the only antiretroviral medication currently approved for PrEP in the United States. Truvada is indicated for use in combination with safe sex practices for PrEP to reduce the risk of sexually acquired HIV infection in adults at high risk. The new guidelines are suggested for sexually active gay men who do not use condoms, heterosexual men and women with high-risk partners who do not use condoms, adults who have regular sex with anyone they know is already infected with HIV, and anyone who shares needles or injects drugs. Since 2010, three separate trials of Truvada in gay men, heterosexual couples, and intravenous drug users have shown that when taken daily, it can greatly reduce the chances of HIV infection. In the study of gay men, among the men who had taken the medicine every day, 99 percent were protected. 6 Medicines in Development HIV/AIDS 2014
  • 7. Facts Facts About HIV/AIDS HIV/AIDS Worldwide1 • At the end of 2013, approximately 35 million people were living with HIV, and some 2.1 million people became newly infected globally. • Sub-Saharan Africa is the most affected region, with nearly 25 million people living with HIV in 2013. That region also accounts for almost 70 percent of the global total of new HIV infections. • In 2013, 12.9 million people living with HIV were receiving antiretroviral therapy (ART) globally. Of those, 11.7 million were receiving ART in low- and middle-income countries. Approximately 740,000 of them were children. • Pediatric coverage lags behind adults with fewer than 1 in 4 children on ART, compared to 1 in 3 adults. Of all adults living with HIV, 38 percent were receiving treatment; however, just 24 percent of all children living with HIV were receiving those lifesaving medicines in 2013. • In 2013, 67 percent of the estimated 1.4 million pregnant women living with HIV in low- and middle-income countries received antiretroviral drugs to avoid transmission to their children, up from 47 percent in 2010. • HIV continues to be a major global public health issue, having claimed more than 39 million lives so far. In 2013, approximately 1.5 million people died from HIV-related causes. HIV/AIDS in the United States2 • An estimated 1,144,500 people ages 13 and older are living with HIV infection, including 180,900 (15.8 percent) who are unaware of their infection. Over the past decade, the number of people living with HIV has increased, while the annual number of new HIV infections has remained relatively stable. • The estimated incidence (new infections) of HIV has remained stable overall in recent years, at approximately 50,000 new HIV infections per year. Within the overall estimates, however, some groups are affected more than others. Men who have sex with men continue to bear the greatest burden of HIV infection, and among races/ethnicities, African Americans continue to be disproportionately affected. • African Americans make up 12 percent of the U.S. population, but accounted for 44 percent of new HIV infections in 2010; Hispanics make up 16 percent of the population, but accounted for 21 percent of new HIV infections in 2010; and men who have sex with men account for 4 percent of the male population, but accounted for 78 percent of new infections in 2010 among men and 63 percent of all new infections. • In 2011, an estimated 32,052 people were diagnosed with AIDS. Overall, an estimated 1,155,792 people in the United States have been diagnosed with AIDS. • An estimated 15,529 people with an AIDS diagnosis died in 2010, and approximately 636,000 people in the United States with an AIDS diagnosis have died overall. The deaths of people with an AIDS diagnosis can be due to any cause—that is, the death may or may not be related to AIDS. HIV/AIDS Economic Impact in the United States2 • A large portion of the economic burden of HIV/AIDS is the medical cost of treating people with HIV. The average annual cost of HIV care in the ART era was estimated to be $23,000 per person in 2010 dollars. The most recent published estimate of lifetime HIV treatment costs was $379,668 in 2010 dollars. • The medical savings from HIV infections averted by U.S. prevention programs from 1991-2006 were estimated to be $129.9 billion with nearly 362,000 infections averted. • Nearly 30 years into the HIV epidemic, HIV continues to take a heavy toll in the United States. More than 1.1 million people are currently living with HIV, nearly 18,000 people with AIDS still die each year, and lifetime medical care for those who become infected with HIV each year is estimated to cost $20 billion. Sources: 1. World Health Organization, www.who.int 2. U.S. Centers for Disease Control and Prevention, www.cdc.gov Medicines in Development HIV/AIDS 2014 7
  • 8. Medicines and Vaccines in Development for HIV/AIDS Antivirals Product Name Sponsor Indication Development Phase* ‘572-Trii (abacavir/dolutegravir/ lamivudine xed-dose combination) ViiV Healthcare Research Triangle Park, NC HIV-1 infection treatment application submitted amdoxovir RFS Pharma Tucker, GA HIV-1 infection treatment Phase II anti-PD-L1 (BMS-936559) Bristol-Myers Squibb Princeton, NJ HIV-1 infection treatment Phase I apricitabine (ATC) Avexa Melbourne, Australia LINK Healthcare Singapore HIV-1 infection treatment (Fast Track) BMS-955176 Bristol-Myers Squibb Princeton, NJ HIV-1 infection treatment Phase II cenicriviroc (CCR2/CCR5 receptor antagonist) Tobira Therapeutics South San Francisco, CA HIV-1 infection treatment Phase II completed cobicistat (PK enhancer) Gilead Sciences Foster City, CA HIV infection treatment application submitted cobicistat/darunavir/ emtricitabine/ tenofovir alafenamide xed-dose combination Gilead Sciences Foster City, CA HIV-1 infection treatment Phase II cobicistat/elvitegravir/ emtricitabine/ tenofovir alafenamide xed-dose combination Gilead Sciences Foster City, CA HIV-1 infection treatment Phase III dapivirine (vaginal ring) International Partnership for Microbicides Silver Spring, MD Janssen RD Ireland Cork, Ireland HIV infection prevention Phase I *For more information about a specifi c medicine or company in this report, please use the website provided. www.viivhealthcare.com www.rfspharma.com www.bms.com Phase III www.avexa.com.au www.linkhealthcare.co www.bms.com www.tobiratherapeutics.com www.gilead.com www.gilead.com www.gilead.com www.ipmglobal.org 8 Medicines in Development HIV/AIDS 2014
  • 9. Medicines and Vaccines in Development for HIV/AIDS Antivirals Product Name Sponsor Indication Development Phase efavirenz/lamivudine/ tenofovir fumarate xed-dose combination Mylan Laboratories Canonsburg, PA HIV-1 infection treatment application submitted www.mylan.com elvitegravir (integrase inhibitor) Gilead Sciences Foster City, CA HIV-1 infection treatment application submitted www.gilead.com F/TAF (emtricitabine/tenofovir alafenamide xed-dose combination) Gilead Sciences Foster City, CA HIV-1 infection treatment Phase III www.gilead.com GSK2838232 (antiviral maturation inhibitor) ViiV Healthcare Research Triangle Park, NC HIV-1 infection treatment Phase I www.viivhealthcare.com HIV attachment inhibitor (BMS-663068) Bristol-Myers Squibb Princeton, NJ HIV-1 infection treatment (Fast Track) Phase II www.bms.com ibalizumab (TMB-355) (viral entry inhibitor) US TaiMed Biologics Irvine, CA HIV-1 infection treatment (Fast Track) Phase II www.taimedbiologics.com lamivudine/raltegravir xed-dose combination Merck Whitehouse Station, NJ HIV-1 infection treatment application submitted www.merck.com MK-1439 (doravirine) Merck Whitehouse Station, NJ HIV-1 infection treatment Phase II www.merck.com Norvir® ritonavir powdered formulation AbbVie North Chicago, IL HIV infection treatment in clinical trials www.abbvie.com Prezista® darunavir and cobicistat (GS-9350) xed-dose combination Janssen Research Development Raritan, NJ HIV-1 infection treatment application submitted www.janssenrnd.com PRO 140 (viral entry inhibitor) CytoDyn Vancouver, WA HIV-1 infection treatment Phase II completed www.cytodyn.com reformulated raltegravir (once daily) Merck Whitehouse Station, NJ HIV-1 infection treatment Phase III www.merck.com rilpivirine (long-acting intramuscular) Janssen Research Development Raritan, NJ HIV-1 infection treatment Phase I www.janssenrnd.com S/GSK1265744 (integrase inhibitor, long acting parenteral formulation) ViiV Healthcare Research Triangle Park, NC HIV-1 infection treatment Phase II www.viivhealthcare.com Medicines in Development HIV/AIDS 2014 9
  • 10. Medicines and Vaccines in Development for HIV/AIDS Antivirals Product Name Sponsor Indication Development Phase tenofovir vaginal gel (NtRTI) CONRAD Arlington, VA HIV infection prevention Phase I www.conrad.org Cell Therapy/Gene Therapy Product Name Sponsor Indication Development Phase Cal-1 (blood stem cell therapy) Calimmune Los Angeles, CA HIV-1 infection treatment Phase I/II www.calimmune.com MazF gene therapy Takara Bio Tokyo, Japan HIV-1 infection treatment Phase I www.takara-bio.com SB-728-T (CCR5 receptor modulator) Sangamo BioSciences Richmond, CA HIV infection treatment Phase II www.sangamo.com Vaccines Product Name Sponsor Indication Development Phase AGS-004 (personalized immunotherapy) Argos Therapeutics Durham, NC HIV-1 infection treatment Phase II www.argostherapeutics.com GOVX-B11 (clade B) (DNA/MVA vaccine) GeoVax Labs Atlanta, GA HIV infection prevention ----------------------------------------- HIV infection treatment Phase II www.geovax.com ----------------------------------------- Phase I www.geovax.com HIV recombinant vaccine GlaxoSmithKline Research Triangle Park, NC HIV-1 immunotherapy Phase II www.gsk.com HIV recombinant vaccine GlaxoSmithKline Research Triangle Park, NC HIV-1 infection prevention Phase I www.gsk.com 10 Medicines in Development HIV/AIDS 2014
  • 11. Medicines and Vaccines in Development for HIV/AIDS Vaccines Product Name Sponsor Indication Development Phase HIV vaccine Novartis Vaccines Diagnostics Cambridge, MA National Institute of Allergy and Infectious Diseases Bethesda, MD HIV infection Phase I www.novartisvaccines.com HIV vaccine (Ad4-EnvC 150) PaxVax San Diego, CA National Institute of Allergy and Infectious Diseases Bethesda, MD HIV infection prevention Phase I www.paxvax.com HIV vaccine (Ad4-mGag) PaxVax Baltimore, MD National Institute of Allergy and Infectious Diseases Bethesda, MD HIV infection prevention Phase I www.paxvax.com HIV vaccine (SAV001) Sumagen Canada London, Canada HIV-1 infection prevention Phase I completed www.sumagen.co.kr HIVAX™ replication-defective HIV-1 vaccine GeneCure Biotechnologies Norcross, GA HIV-1 infection treatment Phase I www.genecure.com LFn-p24-B-C (HIV therapeutic vaccine) Haikou VTI Biological Institute Haikou City, China HIV-1 infection treatment with ART in clinical trials www.haikouvti.com/en PBSVax™ HIV-MAG DNA vaccine Profectus BioSciences Baltimore, MD HIV infection treatment ----------------------------------------- HIV infection prevention Phase I www.profectusbiosciences.net ----------------------------------------- Phase I www.profectusbiosciences.net Pennvax®-B DNA vaccine (clade B) Inovio Pharmaceuticals Blue Bell, PA HIV Vaccine Trials Network Seattle, WA HIV infection prevention and treatment Phase I completed www.inovio.com Pennvax®-G DNA vaccine (clades A, C, D) Inovio Pharmaceuticals Blue Bell, PA National Institute of Allergy and Infectious Diseases Bethesda, MD HIV infection prevention and treatment Phase I www.inovio.com Remune® HIV vaccine Immune Response BioPharma Atlantic City, NJ HIV-1 infection treatment Phase III www.immuneresponsebiopharma. com Medicines in Development HIV/AIDS 2014 11
  • 12. Medicines and Vaccines in Development for HIV/AIDS Vaccines Product Name Sponsor Indication Development Phase RemuneX® HIV combination vaccine Immune Response BioPharma Atlantic City, NJ HIV-1 infection treatment Phase III www.immuneresponsebiopharma. com vacc-4x (intradermal vaccine) Bionor Pharma Oslo, Norway HIV-1 infection treatment combined with Revlimid® ----------------------------------------- HIV-1 infection treatment combined with Istodax® Phase II www.bionorpharma.com ----------------------------------------- Phase II www.bionorpharma.com Defi nitions Application Submitted—An application for marketing has been submitted by the company to the U.S. Food and Drug Administration (FDA). Fast Track—This designation is assigned by the FDA to facilitate the development and expedite the review of drugs to treat serious diseases and ll unmet medical needs. When considering a drug company’s request for Fast Track designation for an investigational drug, the FDA evaluates whether the drug will a ect factors such as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one. Early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process, once a drug receives Fast Track designation. The increase in communication can help to quickly resolve any questions or issues that arise, potentially leading to an earlier drug approval and access by patients. Phase I—Researchers test the investigational drug in a small group of people, usually between 20 and 100 healthy adult volunteers, to evaluate its initial safety and tolerability profile, determine a safe dosage range, and identify potential side effects. Phase II—The investigational drug is given to volunteer patients, usually between 100 and 500, to determine whether the drug is e ective, identify an optimal dose, and to further evaluate its short-term safety. Phase III—The investigational drug is given to a larger, more diverse patient population, often involving between 1,000 and 5,000 patients (but sometimes many more), to generate statistically signi cant evidence to con rm its safety and e ectiveness. Phase III studies are the longest studies and usually take place in multiple sites around the world. The content of this report has been obtained through public, government and industry sources, and the Adis “RD Insight” database based on the latest information. Report current as of August 5, 2014. The medicines in this report include medicines being developed by U.S.-based companies conducting trials in the United States and abroad, PhRMA-member companies conducting trials in the United States and abroad, and foreign companies conducting clinical trials in the United States. The information in this report may not be comprehensive. For more specifi c information about a particular product, contact the individual company directly or go to www.clinicaltrials.gov. The entire series of Medicines in Development is available on PhRMA’s website. A publication of PhRMA’s Communications Public Affairs Department (202) 835-3460 www.phrma.org | www.innovation.org | www.pparx.org Provided as a public service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association. Copyright © 2014 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if proper credit is given. Pharmaceutical Research and Manufacturers of America • 950 F Street, NW, Suite 300, Washington, DC 20004 12 Medicines in Development HIV/AIDS 2014
  • 13. Approved Medicines for HIV/AIDS Entry Inhibitors Selzentry® (maraviroc) ViiV Healthcare Fuzeon® (enfuvirtide) Genentech, Trimeris Integrase Inhibitor Isentress® (raltegravir) Merck Tivicay® (dolutegravir) ViiV Healthcare Nucleoside Reverse Transcriptase Inhibitors (NRTI) Combivir® (lamivudine/zidovudine) ViiV Healthcare Emtriva® (emtricitabine) Gilead Sciences Epivir® (lamivudine) ViiV Healthcare Epzicom® (abacavir/lamivudine) ViiV Healthcare Hivid® (zalcitabine) Roche, marketing discontinued Retrovir® (zidovudine) ViiV Healthcare Trizivir® (abacavir/lamivudine/zidovudine) ViiV Healthcare Videx® (didanosine) Bristol-Myers Squibb Videx® EC (didanosine delayed release) Bristol-Myers Squibb Zerit® (stavudine) Bristol-Myers Squibb Zerit XR® (stavudine extended release) Bristol-Myers Squibb, marketing discontinued Ziagen® (abacavir) ViiV Healthcare Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) Edurant® (rilpivirine) Janssen Therapeutics Intelence® (etravirine) Janssen Therapeutics Rescriptor® (delvaridine mesylate) ViiV Healthcare Sustiva® (efavirenz) Bristol-Myers Squibb Viramune® (nevirapine) Boehringer Ingelheim Pharmaceuticals Viramune XR® (nevirapine extended release) Boehringer Ingelheim Pharmaceuticals Medicines in Development HIV/AIDS 2014 13
  • 14. Approved Medicines for HIV/AIDS Nucleotide Reverse Transcriptase Inhibitor (NtRTI) Viread® (tenofovir disoproxil fumarate) Gilead Sciences Protease Inhibitors Agenerase® (amprenavir) GlaxoSmithKline, Vertex Pharmaceuticals, marketing discontinued Aptivus® (tipranavir) Boehringer Ingelheim Pharmaceuticals Crixivan® (indinavir) Merck Fortovase® (saquinavir soft-gel) Roche, marketing discontinued Invirase® (saquinavir) Genentech Kaletra® (lopinavir/ritonavir) AbbVie Lexiva® (fosamprenavir) ViiV Healthcare, Vertex Pharmaceuticals Norvir® (ritonavir) AbbVie Prezista® (darunavir) Janssen Therapeutics Reyataz® (atazanavir) Bristol-Myers Squibb Viracept® (nelfi navir) ViiV Healthcare Combination Medicines NNRTI/NRTI/NtRTI Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) Bristol-Myers Squibb, Gilead Sciences NRTI/NNRTI/NtRTI Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) Gilead Sciences Integrase Inhibitor/PK Enhancer/NRTI/NtRTI Stribild® (elvitegravor/cobicistat/emtricitabine/tenofvoir disoproxil fumarate) Gilead Sciences NRTI/NtRTI Truvada® (emtricitabine/tenofovir disoproxil fumarate) Gilead Sciences 14 Medicines in Development HIV/AIDS 2014
  • 15. The Drug Discovery, Development and Approval Process Developing a new medicine takes an average of 10-15 years. Of the tens of thousands of compounds screened, only one is approved. The Drug Development and Approval Process The U.S. system of new drug approvals is perhaps the most rigorous in the world. It takes 10-15 years, on average, for an investigational drug to travel from the lab to U.S. patients, according to the Tufts Center for the Study of Drug Development. Tens of thousands of compounds may be screened early in development, but only one ultimately receives approval. Even medicines that reach clinical trials have only a 16 percent chance of being approved. On average, it costs a company $1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development. More recent studies estimate the cost to be even higher. Once a new compound has been identifi ed in the laboratory, medicines are usually developed as follows: Preclinical Testing—A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety. Investigational New Drug Application (IND)— After completing preclinical testing, a company fi les an IND with the U.S. Food and Drug Administration (FDA) to begin to test the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB. Clinical Trials, Phase I—Researchers test the drug in a small group of people, usually between 20 and 100 healthy adult volunteers, to evaluate its initial safety and tolerability profi le, determine a safe dosage range, and identify potential side effects. Clinical Trials, Phase II—The drug is given to volunteer patients, usually between 100 and 500, to see if it is effective, identify an optimal dose, and to further evaluate its short-term safety. Clinical Trials, Phase III—The drug is given to a larger, more diverse patient population, often involving between 1,000 and 5,000 patients (but sometimes many more), to generate statistically signifi cant evidence to confi rm its safety and effectiveness. They are the longest studies, and usually take place in multiple sites around the world. New Drug Application (NDA)/Biologic License Application (BLA)—Following the completion of all three phases of clinical trials, a company analyzes all of the data and fi les an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientifi c information that the company has gathered. Applications typically run 100,000 pages or more. Approval—Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects. Discovering and developing safe and effective new medicines is a long, diffi cult, and expensive process. PhRMA member companies invested an estimated $51.1 billion in research and development in 2013. Medicines in Development HIV/AIDS 2014 15
  • 16. ful l color black white Pharmaceutical Research and Manufacturers of America 950 F Street, NW, Washington, DC 20004 www.phrma.org